176 results on '"Luca, Ceriani"'
Search Results
2. Planning with Always Preferences by Compilation into STRIPS with Action Costs
- Author
-
Luca Ceriani and Alfonso Gerevini
- Abstract
We address planning with always preferences in propositional domains, proposing a new compilation schema for translating a STRIPS problem enriched with always preferences (and possibly also soft goals) into a STRIPS problem with action costs. Our method allows many STRIPS planners to effectively address planning with always preferences and soft goals. An experimental analysis indicates that such basic planners are competitive with current planners using techniques specifically developed to handle always preferences.
- Published
- 2021
- Full Text
- View/download PDF
3. The Role of 2-[18F]-FDG PET/CT in Detecting Richter Transformation in Chronic Lymphocytic Leukemia: A Systematic Review
- Author
-
Luca Giovanella, Domenico Albano, Giorgio Treglia, Raffaele Giubbini, Luca Ceriani, Salvatore Annunziata, Francesco Dondi, and Francesco Bertagna
- Subjects
Oncology ,medicine.medical_specialty ,Richter transformation ,business.industry ,Incidence (epidemiology) ,Chronic lymphocytic leukemia ,Standardized uptake value ,Aggressive lymphoma ,General Medicine ,Cochrane Library ,medicine.disease ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,B-cell chronic lymphocytic leukemia ,Fdg pet ct ,business - Abstract
Richter transformation (RT) is a condition wherein B cell chronic lymphocytic leukemia (CLL) transforms into a more aggressive lymphoma variant. The incidence and the significance of RT detected by 2-[18F]-FDG PET/CT is a clinical challenge and it is not widely investigated in the literature. The aim of this systematic review was to analyze published data about the potential role of 2-[18F]-FDG PET/CT in detecting RT. A comprehensive computer literature search of the PubMed/MEDLINE, Embase and Cochrane library databases was conducted up to December 2020. Thirteen studies (1336 patients with CLL) were selected. The maximum standardized uptake value (SUVmax) was the most common metabolic parameter used to detect RT. An SUVmax of 5 had an average overall sensitivity of 87% (range: 71–96%), an average overall specificity of 49% (range: 4–80%), an average positive predictive value of 41% (range: 16–53%) and an average negative predictive value of 84% (range: 33–97%). Other metabolic variables were only marginally investigated, with promising results. 2-[18F]-FDG PET/CT imaging may play an important role in the detection of RT in CLL, based on the high metabolic activity of the nodal lesions that transformed into aggressive lymphomas. 2-[18F]-FDG PET/CT has high negative predictive value for evaluating RT.
- Published
- 2021
- Full Text
- View/download PDF
4. D
- Author
-
Luca, Ceriani and Emanuele, Zucca
- Published
- 2022
5. Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib
- Author
-
Adalgisa Condoluci, Lisa Milan, Gabriela Forestieri, Lodovico Terzi di Bergamo, Valeria Spina, Alessio Bruscaggin, Clara Deambrogi, Riccardo Moia, Marina Deodato, Gaby Fahrni, Roberta Mattarucchi, Michele Merli, Bernhard Gerber, Georg Stussi, Francesco Passamonti, Michael Gregor, Alessandra Tedeschi, Gianluca Gaidano, Davide Rossi, and Luca Ceriani
- Subjects
Cancer Research ,Neoplasm, Residual ,Oncology ,Humans ,Hematology ,General Medicine ,Leukemia, Lymphocytic, Chronic, B-Cell - Published
- 2022
6. Author response for 'Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib'
- Author
-
null Adalgisa Condoluci, null Lisa Milan, null Gabriela Forestieri, null Lodovico Terzi di Bergamo, null Valeria Spina, null Alessio Bruscaggin, null Clara Deambrogi, null Riccardo Moia, null Marina Deodato, null Gaby Fahrni, null Roberta Mattarucchi, null Michele Merli, null Bernhard Gerber, null Georg Stussi, null Francesco Passamonti, null Michael Gregor, null Alessandra Tedeschi, null Gianluca Gaidano, null Davide Rossi, and null Luca Ceriani
- Published
- 2022
- Full Text
- View/download PDF
7. International Impact of COVID-19 on the Diagnosis of Heart Disease
- Author
-
Einstein, A. J., Shaw, L. J., Hirschfeld, C., Williams, M. C., Villines, T. C., Better, N., Vitola, J. V., Cerci, R., Dorbala, S., Raggi, P., Choi, A. D., Lu, B., Sinitsyn, V., Sergienko, V., Kudo, T., Norgaard, B. L., Maurovich-Horvat, P., Campisi, R., Milan, E., Louw, L., Allam, A. H., Bhatia, M., Malkovskiy, E., Goebel, B., Cohen, Y., Randazzo, M., Narula, J., Pascual, T. N. B., Pynda, Y., Dondi, M., Gerd Hinterleitner, Paez D., Yao, Lu, Olga, Morozova, Zhuoran, Xu, Juan, Lopez-Mattei, Purvi, Parwani, Mohammad Nawaz Nasery, Artan, Goda, Ervina, Shirka, Rabie, Benlabgaa, Salah, Bouyoucef, Abdelkader, Medjahedi, Qais, Nailli, Mariela, Agolti, Roberto Nicolas Aguero, Maria Del Carmen Alak, Lucia Graciela Alberguina, Guillermo, Arroñada, Andrea, Astesiano, Alfredo, Astesiano, Carolina Bas Norton, Pablo, Benteo, Juan, Blanco, Juan Manuel Bonelli, Jose Javier Bustos, Raul, Cabrejas, Jorge, Cachero, Alejandro, Canderoli, Silvia, Carames, Patrícia, Carrascosa, Ricardo, Castro, Oscar, Cendoya, Luciano Martin Cognigni, Carlos, Collaud, Claudia, Cortes, Javier, Courtis, Daniel, Cragnolino, Mariana, Daicz, Alejandro De La Vega, Silvia Teresa De Maria, Horacio Del Riego, Fernando, Dettori, Alejandro, Deviggiano, Laura, Dragonetti, Mario, Embon, Ruben Emilio Enriquez, Jorge, Ensinas, Fernando, Faccio, Adolfo, Facello, Diego, Garofalo, Ricardo, Geronazzo, Natalia, Gonza, Lucas, Gutierrez, Miguel Angel Guzzo, Victor, Hasbani, Melina, Huerin, Victor, Jäger, Julio Manuel Lewkowicz, Maria Nieves, A López De Munaín, Jose Maria Lotti, Alejandra, Marquez, Osvaldo, Masoli, Edgardo, Mastrovito, Matias, Mayoraz, Graciela Eva Melado, Anibal, Mele, Maria Fernanda Merani, Alejandro Horacio Meretta, Susana, Molteni, Marcos, Montecinos, Eduardo, Noguera, Carlos, Novoa, Claudio Pereyra Sueldo, Sebastian Perez Ascani, Pablo, Pollono, Maria Paula Pujol, Alejandro, Radzinschi, Gustavo, Raimondi, Marcela, Redruello, Marina, Rodríguez, Matías, Rodríguez, Romina Lorena Romero, Arturo Romero Acuña, Federico, Rovaletti, Lucas San Miguel, Lucrecia, Solari, Bruno, Strada, Sonia, Traverso, Sonia Simona Traverzo, Maria Del Huerto Velazquez Espeche, Juan Sebastian Weihmuller, Juan, Wolcan, Susana, Zeffiro, Mari, Sakanyan, Scott, Beuzeville, Raef, Boktor, Patrick, Butler, Jennifer, Calcott, Loretta, Carr, Virgil, Chan, Charles, Chao, Woon, Chong, Mark, Dobson, D'Arne, Downie, Girish, Dwivedi, Barry, Elison, Jean, Engela, Roslyn, Francis, Anand, Gaikwad, Ashok Gangasandra Basavaraj, Bruce, Goodwin, Robert, Greenough, Christian, Hamilton-Craig, Victar, Hsieh, Subodh, Joshi, Karin, Lederer, Kenneth, Lee, Joseph, Lee, John, Magnussen, Nghi, Mai, Gordon, Mander, Fiona, Murton, Dee, Nandurkar, Johanne, Neill, Edward, O'Rourke, Patricia, O'Sullivan, George, Pandos, Kunthi, Pathmaraj, Alexander, Pitman, Rohan, Poulter, Manuja, Premaratne, David, Prior, Lloyd, Ridley, Natalie, Rutherford, Hamid, Salehi, Connor, Saunders, Luke, Scarlett, Sujith, Seneviratne, Deepa, Shetty, Ganesh, Shrestha, Jonathan, Shulman, Vijay, Solanki, Tony, Stanton, Murch, Stuart, Michael, Stubbs, Ian, Swainson, Kim, Taubman, Andrew, Taylor, Paul, Thomas, Steven, Unger, Anthony, Upton, Shankar, Vamadevan, William Van Gaal, Johan, Verjans, Demetrius, Voutnis, Victor, Wayne, Peter, Wilson, David, Wong, Kirby, Wong, John, Younger, Gudrun, Feuchtner, Siroos, Mirzaei, Konrad, Weiss, Natallia, Maroz-Vadalazhskaya, Olivier, Gheysens, Filip, Homans, Rodrigo, Moreno-Reyes, Agnès, Pasquet, Veronique, Roelants, Caroline, M Van De Heyning, Raúl Araujo Ríos, Valentina, Soldat-Stankovic, Sinisa, Stankovic, Maria Helena Albernaz Siqueira, Augusto, Almeida, Paulo Henrique Alves Togni, Jose Henrique Andrade, Luciana, Andrade, Carlos, Anselmi, Roberta, Araújo, Guilherme, Azevedo, Sabbrina, Bezerra, Rodrigo, Biancardi, Gabriel Blacher Grossman, Simone, Brandão, Diego Bromfman Pianta, Lara, Carreira, Bruno, Castro, Tien, Chang, Fernando Cunali Jr, Roberto, Cury, Roberto, Dantas, Fernando de Amorim Fernandes, Andrea De Lorenzo, Robson De Macedo Filho, Fernanda, Erthal, Fabio, Fernandes, Juliano, Fernandes, Thiago Ferreira De Souza, Wilson Furlan Alves, Bruno, Ghini, Luiz, Goncalves, Ilan, Gottlieb, Marcelo, Hadlich, Vinícius, Kameoka, Ronaldo, Lima, Adna, Lima, Rafael Willain Lopes, Ricardo Machado, E Silva, Tiago, Magalhães, Fábio Martins Silva, Luiz Eduardo Mastrocola, Fábio, Medeiros, José Claudio Meneghetti, Vania, Naue, Danilo, Naves, Roberto, Nolasco, Cesar, Nomura, Joao Bruno Oliveira, Eduardo, Paixao, Filipe Penna De Carvalho, Ibraim, Pinto, Priscila, Possetti, Mayra, Quinta, Rodrigo Rizzo Nogueira Ramos, Ricardo, Rocha, Alfredo, Rodrigues, Carlos, Rodrigues, Leila, Romantini, Adelina, Sanches, Sara, Santana, Leonardo Sara da Silva, Paulo, Schvartzman, Cristina Sebastião Matushita, Tiago, Senra, Afonso, Shiozaki, Maria Eduarda Menezes de Siqueira, Cristiano, Siqueira, Paola, Smanio, Carlos Eduardo Soares, José Soares Junior, Marcio Sommer Bittencourt, Bernardo, Spiro, Cláudio Tinoco Mesquita, Jorge, Torreao, Rafael, Torres, Marly, Uellendahl, Guilherme Urpia Monte, Otávia, Veríssimo, Estevan Vieira Cabeda, Felipe Villela Pedras, Roberto, Waltrick, Marcello, Zapparoli, Hamid, Naseer, Marina, Garcheva-Tsacheva, Irena, Kostadinova, Youdaline, Theng, Gad, Abikhzer, Rene, Barette, Benjamin, Chow, Dominique, Dabreo, Matthias, Friedrich, Ria, Garg, Mohammed Nassoh Hafez, Chris, Johnson, Marla, Kiess, Jonathon, Leipsic, Eugene, Leung, Robert, Miller, Anastasia, Oikonomou, Stephan, Probst, Idan, Roifman, Gary, Small, Vikas, Tandon, Adwait, Trivedi, James, White, Katherine, Zukotynski, Jose, Canessa, Gabriel Castro Muñoz, Carmen, Concha, Pablo, Hidalgo, Cesar, Lovera, Teresa, Massardo, Luis Salazar Vargas, Pedro, Abad, Harold, Arturo, Sandra, Ayala, Luis, Benitez, Alberto, Cadena, Carlos, Caicedo, Antonio Calderón Moncayo, Sharon, Gomez, Claudia, T Gutierrez Villamil, Claudia, Jaimes, Juan Luis Londoño Blair, Luz, Pabon, Mauricio, Pineda, Juan Carlos Rojas, Diego, Ruiz, Manuel Valencia Escobar, Andres, Vasquez, Damiana, Vergel, Alejandro, Zuluaga, Isabel Berrocal Gamboa, Gabriel, Castro, Ulises, González, Ana, Baric, Tonci, Batinic, Maja, Franceschi, Maja Hrabak Paar, Mladen, Jukic, Petar, Medakovic, Viktor, Persic, Marina, Prpic, Ante, Punda, Juan Felipe Batista, Juan Manuel Gómez Lauchy, Yamile Marcos Gutierrez, Rayner, Menéndez, Amalia, Peix, Luis, Rochela, Christoforos, Panagidis, Ioannis, Petrou, Vaclav, Engelmann, Milan, Kaminek, Vladimír, Kincl, Otto, Lang, Milan, Simanek, Jawdat, Abdulla, Morten, Bøttcher, Mette, Christensen, Lars Christian Gormsen, Philip, Hasbak, Søren, Hess, Paw, Holdgaard, Allan, Johansen, Kasper, Kyhl, Kristian Altern Øvrehus, Niels Peter Rønnow Sand, Rolf, Steffensen, Anders, Thomassen, Zerahn, Bo, Alfredo, Perez, Giovanni Alejandro Escorza Velez, Mayra Sanchez Velez, Islam Shawky Abdel Aziz, Mahasen, Abougabal, Taghreed, Ahmed, Ahmed, Asfour, Mona, Hassan, Alia, Hassan, Ahmed, Ibrahim, Sameh, Kaffas, Ahmed, Kandeel, Mohamed Mandour Ali, Ahmad, Mansy, Hany, Maurice, Sherif, Nabil, Mahmoud, Shaaban, Ana Camila Flores, Anne, Poksi, Juhani, Knuuti, Velipekka, Kokkonen, Martti, Larikka, Valtteri, Uusitalo, Matthieu, Bailly, Samuel, Burg, Jean-François, Deux, Vincent, Habouzit, Fabien, Hyafil, Olivier, Lairez, Franck, Proffit, Hamza, Regaieg, Laure, Sarda-Mantel, Vania, Tacher, Roman, P Schneider, Harold, Ayetey, George, Angelidis, Aikaterini, Archontaki, Sofia, Chatziioannou, Ioannis, Datseris, Christina, Fragkaki, Panagiotis, Georgoulias, Sophia, Koukouraki, Maria, Koutelou, Eleni, Kyrozi, Evangelos, Repasos, Petros, Stavrou, Pipitsa, Valsamaki, Carla, Gonzalez, Goleat, Gutierrez, Alejandro, Maldonado, Klara, Buga, Ildiko, Garai, Erzsébet, Schmidt, Balint, Szilveszter, Edit, Várady, Nilesh, Banthia, Jinendra Kumar Bhagat, Rishi, Bhargava, Vivek, Bhat, Partha, Choudhury, Vijay Sai Chowdekar, Aparna, Irodi, Shashank, Jain, Elizabeth, Joseph, Sukriti, Kumar, Girijanandan, Mahapatra, Deepanjan, Mitra, Bhagwant Rai Mittal, Ahmad, Ozair, Chetan, Patel, Tapan, Patel, Ravi, Patel, Shivani, Patel, Sudhir, Saxena, Shantanu, Sengupta, Santosh, Singh, Bhanupriya, Singh, Ashwani, Sood, Atul, Verma, Erwin, Affandi, Padma Savenadia Alam, Edison, Edison, Gani, Gunawan, Habusari, Hapkido, Basuki, Hidayat, Aulia, Huda, Anggoro Praja Mukti, Djoko, Prawiro, Erwin Affandi Soeriadi, Hilman, Syawaluddin, Amjed, Albadr, Majid, Assadi, Farshad, Emami, Golnaz, Houshmand, Majid, Maleki, Maryam Tajik Rostami, Seyed Rasoul Zakavi, Eed Abu Zaid, Svetlana, Agranovich, Yoav, Arnson, Rachel, Bar-Shalom, Alex, Frenkel, Galit, Knafo, Rachel, Lugassi, Israel Shlomo Maor Moalem, Maya, Mor, Noam, Muskal, Sara, Ranser, Aryeh, Shalev, Domenico, Albano, Pierpaolo, Alongi, Gaspare, Arnone, Elisa, Bagatin, Sergio, Baldari, Matteo, Bauckneht, Paolo, Bertelli, Francesco, Bianco, Rachele, Bonfiglioli, Roberto, Boni, Andrea, Bruno, Isabella, Bruno, Elena, Busnardo, Elena, Califaretti, Luca, Camoni, Aldo, Carnevale, Roberta, Casoni, Armando Ugo Cavallo, Giorgio, Cavenaghi, Franca, Chierichetti, Marcello, Chiocchi, Corrado, Cittanti, Mauro, Colletta, Umberto, Conti, Alberto, Cossu, Alberto, Cuocolo, Marco, Cuzzocrea, Maria Luisa De Rimini, Giuseppe De Vincentis, Eleonora Del Giudice, Alberico Del Torto, DELLA TOMMASINA, Veronica, Rexhep, Durmo, Erba, PAOLA ANNA, Laura, Evangelista, Riccardo, Faletti, Evelina, Faragasso, Mohsen, Farsad, Paola, Ferro, Luigia, Florimonte, Viviana, Frantellizzi, Fabio Massimo Fringuelli, Marco, Gatti, Angela, Gaudiano, Alessia, Gimelli, Raffaele, Giubbini, Francesca, Giuffrida, Salvatore, Ialuna, Riccardo, Laudicella, Lucia, Leccisotti, Lucia, Leva, Liga, Riccardo, Carlo, Liguori, Giampiero, Longo, Margherita, Maffione, Maria Elisabetta Mancini, Claudio, Marcassa, Barbara, Nardi, Sara, Pacella, Giovanna, Pepe, Gianluca, Pontone, Sabina, Pulizzi, Natale, Quartuccio, Lucia, Rampin, Fabrizio, Ricci, Pierluigi, Rossini, Giuseppe, Rubini, Vincenzo, Russo, Gian Mauro Sacchetti, Gianmario, Sambuceti, Massimo, Scarano, Roberto, Sciagrà, Massimiliano, Sperandio, Antonella, Stefanelli, Guido, Ventroni, Stefania, Zoboli, Dainia, Baugh, Duane, Chambers, Ernest, Madu, Felix, Nunura, Hiroshi, Asano, Chimura Misato Chimura, Shinichiro, Fujimoto, Koichiro, Fujisue, Tomohisa, Fukunaga, Yoshimitsu, Fukushima, Kae, Fukuyama, Jun, Hashimoto, Yasutaka, Ichikawa, Nobuo, Iguchi, Masamichi, Imai, Anri, Inaki, Hayato, Ishimura, Satoshi, Isobe, Toshiaki, Kadokami, Takao, Kato, Shinichiro, Kumita, Hirotaka, Maruno, Hiroyuki, Mataki, Masao, Miyagawa, Ryota, Morimoto, Masao, Moroi, Shigeki, Nagamachi, Kenichi, Nakajima, Tomoaki, Nakata, Ryo, Nakazato, Mamoru, Nanasato, Masanao, Naya, Takashi, Norikane, Yasutoshi, Ohta, Satoshi, Okayama, Atsutaka, Okizaki, Yoichi, Otomi, Hideki, Otsuka, Masaki, Saito, Sakata Yasushi Sakata, Masayoshi, Sarai, Daisuke, Sato, Shinya, Shiraishi, Yoshinobu, Suwa, Kentaro, Takanami, Kazuya, Takehana, Junichi, Taki, Nagara, Tamaki, Yasuyo, Taniguchi, Hiroki, Teragawa, Nobuo, Tomizawa, Kenichi, Tsujita, Kyoko, Umeji, Yasushi, Wakabayashi, Shinichiro, Yamada, Shinya, Yamazaki, Tatsuya, Yoneyama, Mohammad, Rawashdeh, Daultai, Batyrkhanov, Tairkhan, Dautov, Khalid, Makhdomi, Kevin, Ombati, Faridah, Alkandari, Masoud, Garashi, Tchoyoson Lim Coie, Sonexay, Rajvong, Artem, Kalinin, Marika, Kalnina, Mohamad, Haidar, Renata, Komiagiene, Giedre, Kviecinskiene, Mindaugas, Mataciunas, Donatas, Vajauskas, Christian, Picard, Noor Khairiah, A Karim, Luise, Reichmuth, Anthony, Samuel, Mohammad Aaftaab Allarakha, Ambedhkar Shantaram Naojee, Erick, Alexanderson-Rosas, Erika, Barragan, Alejandro Becerril González-Montecinos, Manuel, Cabada, Daniel Calderon Rodriguez, Isabel, Carvajal-Juarez, Violeta, Cortés, Filiberto, Cortés, Erasmo De La Peña, Manlio, Gama-Moreno, Luis, González, Nelsy Gonzalez Ramírez, Moisés, Jiménez-Santos, Luis, Matos, Edgar, Monroy, Martha, Morelos, Mario, Ornelas, Jose Alberto Ortga Ramirez, Andrés, Preciado-Anaya, Óscar Ulises Preciado-Gutiérrez, Adriana Puente Barragan, Sandra Graciela Rosales Uvera, Sigelinda, Sandoval, Miguel Santaularia Tomas, Lilia, M Sierra-Galan, Silvia, Siu, Enrique, Vallejo, Mario, Valles, Marc, Faraggi, Erdenechimeg, Sereegotov, Srdja, Ilic, Nozha, Ben-Rais, Nadia Ismaili Alaoui, Sara, Taleb, Khin Pa Pa Myo, Phyo Si Thu, Ram Kumar Ghimire, Bijoy, Rajbanshi, Peter, Barneveld, Andor, Glaudemans, Jesse, Habets, Klaas Pieter Koopmans, Jeroen, Manders, Stefan, Pool, Arthur, Scholte, Asbjørn, Scholtens, Riemer, Slart, Paul, Thimister, Erik-Jan Van Asperen, Niels, Veltman, Derk, Verschure, Nils, Wagenaar, John, Edmond, Chris, Ellis, Kerryanne, Johnson, Ross, Keenan, Shaw Hua Anthony Kueh, Christopher, Occleshaw, Alexander, Sasse, Andrew, To, Niels Van Pelt, Calum, Young, Teresa, Cuadra, Hector Bladimir Roque Vanegas, Idrissa Adamou Soli, Djibrillou Moussa Issoufou, Tolulope, Ayodele, Chibuzo, Madu, Yetunde, Onimode, Elen, Efros-Monsen, Signe Helene Forsdahl, Jenni-Mari Hildre Dimmen, Arve, Jørgensen, Isabel, Krohn, Pål, Løvhaugen, Anders Tjellaug Bråten, Humoud Al Dhuhli, Faiza Al Kindi, Naeema, Al-Bulushi, Zabah, Jawa, Naima, Tag, Muhammad Shehzad Afzal, Shazia, Fatima, Muhammad Numair Younis, Musab, Riaz, Mohammad, Saadullah, Yariela, Herrera, Dora, Lenturut-Katal, Manuel Castillo Vázquez, José, Ortellado, Afroza, Akhter, Dianbo, Cao, Stephen, Cheung, Dai, Xu, Lianggeng, Gong, Dan, Han, Yang, Hou, Caiying, Li, Tao, Li, Dong, Li, Sijin, Li, Jinkang, Liu, Hui, Liu, Ming Yen Ng, Kai, Sun, Gongshun, Tang, Jian, Wang, Ximing, Wang, Zhao-Qian, Wang, Yining, Wang, Yifan, Wang, Jiang, Wu, Zhifang, Wu, Liming, Xia, Jiangxi, Xiao, Lei, Xu, Youyou, Yang, Yin, Wu, Jianqun, Yu, Yuan, Li, Tong, Zhang, Longjiang, Zhang, Yong-Gao, Zhang, Xiaoli, Zhang, Zhu, Li, Ana, Alfaro, Paz, Abrihan, Asela, Barroso, Eric, Cruz, Marie Rhiamar Gomez, Vincent Peter Magboo, John Michael Medina, Jerry, Obaldo, Davidson, Pastrana, Christian Michael Pawhay, Alvin, Quinon, Jeanelle Margareth Tang, Bettina, Tecson, Kristine Joy Uson, Mila, Uy, Magdalena, Kostkiewicz, Jolanta, Kunikowska, Nuno, Bettencourt, Guilhermina, Cantinho, Antonio, Ferreira, Ghulam, Syed, Samer, Arnous, Said, Atyani, Angela, Byrne, Tadhg, Gleeson, David, Kerins, Conor, Meehan, David, Murphy, Mark, Murphy, John, Murray, Julie, O'Brien, Ji-In, Bang, Henry, Bom, Sang-Geon, Cho, Chae Moon Hong, Su Jin Jang, Yong Hyu Jeong, Won Jun Kang, Ji-Young, Kim, Jaetae, Lee, Chang Kyeong Namgung, Young, So, Kyoung Sook Won, Venjamin, Majstorov, Marija, Vavlukis, Barbara Gužic Salobir, Monika, Štalc, Theodora, Benedek, Imre, Benedek, Raluca, Mititelu, Claudiu Adrian Stan, Alexey, Ansheles, Olga, Dariy, Olga, Drozdova, Nina, Gagarina, Vsevolod Milyevich Gulyaev, Irina, Itskovich, Anatoly, Karalkin, Alexander, Kokov, Ekaterina, Migunova, Viktor, Pospelov, Daria, Ryzhkova, Guzaliya, Saifullina, Svetlana, Sazonova, Irina, Shurupova, Tatjana, Trifonova, Wladimir Yurievich Ussov, Margarita, Vakhromeeva, Nailya, Valiullina, Konstantin, Zavadovsky, Kirill, Zhuravlev, Mirvat, Alasnag, Subhani, Okarvi, Dragana Sobic Saranovic, Felix, Keng, Jia Hao Jason See, Ramkumar, Sekar, Min Sen Yew, Andrej, Vondrak, Shereen, Bejai, George, Bennie, Ria, Bester, Gerrit, Engelbrecht, Osayande, Evbuomwan, Harlem, Gongxeka, Magritha Jv Vuuren, Mitchell, Kaplan, Purbhoo, Khushica, Hoosen, Lakhi, Nico, Malan, Katarina, Milos, Moshe, Modiselle, Stuart, More, Mathava, Naidoo, Leonie, Scholtz, Mboyo, Vangu, Santiago, Aguadé-Bruix, Isabel, Blanco, Antonio, Cabrera, Alicia, Camarero, Irene, Casáns-Tormo, Hug, Cuellar-Calabria, Albert, Flotats, Maria Eugenia Fuentes Cañamero, María Elia García, Amelia, Jimenez-Heffernan, Rubén, Leta, Javier Lopez Diaz, Luis, Lumbreras, Juan Javier Marquez-Cabeza, Francisco, Martin, Anxo Martinez de Alegria, Francisco, Medina, Maria Pedrera Canal, Virginia, Peiro, Virginia, Pubul-Nuñez, Juan Ignacio Rayo Madrid, Cristina Rodríguez Rey, Ricardo Ruano Perez, Joaquín, Ruiz, Gertrudis Sabatel Hernández, Ana, Sevilla, Nahla, Zeidán, Damayanthi, Nanayakkara, Chandraguptha, Udugama, Magnus, Simonsson, Hatem, Alkadhi, Ronny Ralf Buechel, Peter, Burger, Luca, Ceriani, Bart De Boeck, Christoph, Gräni, Alix Juillet de Saint Lager Lucas, Christel, H Kamani, Nadine, Kawel-Boehm, Robert, Manka, John, O Prior, Axel, Rominger, Jean-Paul, Vallée, Benjapa, Khiewvan, Teerapon, Premprabha, Tanyaluck, Thientunyakit, Ali, Sellem, Kemal Metin Kir, Haluk, Sayman, Mugisha Julius Sebikali, Zerida, Muyinda, Yaroslav, Kmetyuk, Pavlo, Korol, Olena, Mykhalchenko, Volodymyr, Pliatsek, Maryna, Satyr, Batool, Albalooshi, Mohamed Ismail Ahmed Hassan, Jill, Anderson, Punit, Bedi, Thomas, Biggans, Anda, Bularga, Russell, Bull, Rajesh, Burgul, John-Paul, Carpenter, Duncan, Coles, David, Cusack, Aparna, Deshpande, John, Dougan, Timothy, Fairbairn, Alexia, Farrugia, Deepa, Gopalan, Alistair, Gummow, Prasad Guntur Ramkumar, Mark, Hamilton, Mark, Harbinson, Thomas, Hartley, Benjamin, Hudson, Nikhil, Joshi, Michael, Kay, Andrew, Kelion, Azhar, Khokhar, Jamie, Kitt, Ken, Lee, Chen, Low, Sze Mun Mak, Ntouskou, Marousa, Jon, Martin, Elisa, Mcalindon, Leon, Menezes, Gareth, Morgan-Hughes, Alastair, Moss, Anthony, Murray, Edward, Nicol, Dilip, Patel, Charles, Peebles, Francesca, Pugliese, Jonathan Carl Luis Rodrigues, Christopher, Rofe, Nikant, Sabharwal, Rebecca, Schofield, Thomas, Semple, Naveen, Sharma, Peter, Strouhal, Deepak, Subedi, William, Topping, Katharine, Tweed, Jonathan, Weir-Mccall, Suhny, Abbara, Taimur, Abbasi, Brian, Abbott, Shady, Abohashem, Sandra, Abramson, Tarek, Al-Abboud, Mouaz, Al-Mallah, Omar, Almousalli, Karthikeyan, Ananthasubramaniam, Mohan Ashok Kumar, Jeffrey, Askew, Lea, Attanasio, Mallory, Balmer-Swain, Richard, R Bayer, Adam, Bernheim, Sabha, Bhatti, Erik, Bieging, Ron, Blankstein, Stephen, Bloom, Sean, Blue, David, Bluemke, Andressa, Borges, Kelley, Branch, Paco, Bravo, Jessica, Brothers, Matthew, Budoff, Renée, Bullock-Palmer, Angela, Burandt, Floyd, W Burke, Kelvin, Bush, Candace, Candela, Elizabeth, Capasso, Joao, Cavalcante, Donald, Chang, Saurav, Chatterjee, Yiannis, Chatzizisis, Michael, Cheezum, Tiffany, Chen, Jennifer, Chen, Marcus, Chen, Andrew, Choi, James, Clarcq, Ayreen, Cordero, Matthew, Crim, Sorin, Danciu, Bruce, Decter, Nimish, Dhruva, Neil, Doherty, Rami, Doukky, Anjori, Dunbar, William, Duvall, Rachael, Edwards, Kerry, Esquitin, Husam, Farah, Emilio, Fentanes, Maros, Ferencik, Daniel, Fisher, Daniel, Fitzpatrick, Cameron, Foster, Tony, Fuisz, Michael, Gannon, Lori, Gastner, Myron, Gerson, Brian, Ghoshhajra, Alan, Goldberg, Brian, Goldner, Jorge, Gonzalez, Rosco, Gore, Sandra, Gracia-López, Fadi, Hage, Agha, Haider, Sofia, Haider, Yasmin, Hamirani, Karen, Hassen, Mallory, Hatfield, Carolyn, Hawkins, Katie, Hawthorne, Nicholas, Heath, Robert, Hendel, Phillip, Hernandez, Gregory, Hill, Stephen, Horgan, Jeff, Huffman, Lynne, Hurwitz, Ami, Iskandrian, Rajesh, Janardhanan, Christine, Jellis, Scott, Jerome, Dinesh, Kalra, Summanther, Kaviratne, Fernando, Kay, Faith, Kelly, Omar, Khalique, Mona, Kinkhabwala, George Kinzfogl Iii, Jacqueline, Kircher, Rachael, Kirkbride, Michael, Kontos, Anupama, Kottam, Joseph, Krepp, Jay, Layer, Steven, H Lee, Jeffrey, Leppo, John, Lesser, Steve, Leung, Howard, Lewin, Diana, Litmanovich, Yiyan, Liu, Kathleen, Magurany, Jeremy, Markowitz, Amanda, Marn, Stephen, E Matis, Michael, Mckenna, Tony, Mcrae, Fernando, Mendoza, Michael, Merhige, David, Min, Chanan, Moffitt, Karen, Moncher, Warren, Moore, Shamil, Morayati, Michael, Morris, Mahmud, Mossa-Basha, Zorana, Mrsic, Venkatesh, Murthy, Prashant, Nagpal, Kyle, Napier, Katarina, Nelson, Prabhjot, Nijjar, Medhat, Osman, Edward, Passen, Amit, Patel, Pravin, Patil, Ryan, Paul, Lawrence, Phillips, Venkateshwar, Polsani, Rajaram, Poludasu, Brian, Pomerantz, Thomas, Porter, Ryan, Prentice, Amit, Pursnani, Mark, Rabbat, Suresh, Ramamurti, Florence, Rich, Hiram Rivera Luna, Austin, Robinson, Kim, Robles, Cesar, Rodríguez, Mark, Rorie, John, Rumberger, Raymond, Russell, Philip, Sabra, Diego, Sadler, Mary, Schemmer, U Joseph Schoepf, Samir, Shah, Nishant, Shah, Sujata, Shanbhag, Gaurav, Sharma, Steven, Shayani, Jamshid, Shirani, Pushpa, Shivaram, Steven, Sigman, Mitch, Simon, Ahmad, Slim, David, Smith, Alexandra, Smith, Prem, Soman, Aditya, Sood, Monvadi Barbara Srichai-Parsia, James, Streeter, Albert, T Ahmed Tawakol, Dustin, Thomas, Randall, Thompson, Tara, Torbet, Desiree, Trinidad, Shawn, Ullery, Samuel, Unzek, Seth, Uretsky, Srikanth, Vallurupalli, Vikas, Verma, Alfonso, Waller, Ellen, Wang, Parker, Ward, Gaby, Weissman, George, Wesbey, Kelly, White, David, Winchester, David, Wolinsky, Sandra, Yost, Michael, Zgaljardic, Omar, Alonso, Mario, Beretta, Rodolfo, Ferrando, Miguel, Kapitan, Fernando, Mut, Omoa, Djuraev, Gulnora, Rozikhodjaeva, Ha Le Ngoc, Son Hong Mai, Xuan Canh Nguyen, Einstein, A. J., Shaw, L. J., Hirschfeld, C., Williams, M. C., Villines, T. C., Better, N., Vitola, J. V., Cerci, R., Dorbala, S., Raggi, P., Choi, A. D., Lu, B., Sinitsyn, V., Sergienko, V., Kudo, T., Norgaard, B. L., Maurovich-Horvat, P., Campisi, R., Milan, E., Louw, L., Allam, A. H., Bhatia, M., Malkovskiy, E., Goebel, B., Cohen, Y., Randazzo, M., Narula, J., Pascual, T. N. B., Pynda, Y., Dondi, M., Paez, D., Cuocolo, A., Einstein, A, Shaw, L, Hirschfeld, C, Williams, M, Villines, T, Better, N, Vitola, J, Cerci, R, Dorbala, S, Raggi, P, Choi, A, Lu, B, Sinitsyn, V, Sergienko, V, Kudo, T, Norgaard, B, Maurovich-Horvat, P, Campisi, R, Milan, E, Louw, L, Allam, A, Bhatia, M, Malkovskiy, E, Goebel, B, Cohen, Y, Randazzo, M, Narula, J, Pascual, T, Pynda, Y, Dondi, M, Paez, D, Pacella, S, and Erba, P
- Subjects
INCAPS COVID Investigators Group ,Heart disease ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Diagnostic Techniques, Cardiovascular ,coronavirus ,global health ,IAEA ,Disease ,Telehealth ,Cardiorespiratory Medicine and Haematology ,030204 cardiovascular system & hematology ,Cardiovascular ,0302 clinical medicine ,cardiovascular disease ,cardiac testing ,COVID-19 ,diagnostic techniques, cardiovascular ,health care surveys ,heart diseases ,humans ,international agencies ,Pandemic ,Global health ,030212 general & internal medicine ,COVID-19 Heart Disease ,Cause of death ,STATEMENT ,Heart Disease ,International Agencie ,Public Health and Health Services ,Biomedical Imaging ,Cardiology and Cardiovascular Medicine ,Human ,medicine.medical_specialty ,Heart Diseases ,03 medical and health sciences ,Clinical Research ,medicine ,Humans ,Personal protective equipment ,Heart Disease - Coronary Heart Disease ,business.industry ,International Agencies ,medicine.disease ,the ,coronaviru ,Diagnostic Techniques ,Good Health and Well Being ,Clinical research ,Cardiovascular System & Hematology ,Health Care Survey ,Health Care Surveys ,Emergency medicine ,Global Health ,business - Abstract
BACKGROUND The coronavirus disease 2019 (COVID-19) pandemic has adversely affected diagnosis and treatment of noncommunicable diseases. Its effects on delivery of diagnostic care for cardiovascular disease, which remains the leading cause of death worldwide, have not been quantified. OBJECTIVES The study sought to assess COVID-19`s impact on global cardiovascular diagnostic procedural volumes and safety practices. METHODS The International Atomic Energy Agency conducted a worldwide survey assessing alterations in cardiovascular procedure volumes and safety practices resulting from COVID-19. Noninvasive and invasive cardiac testing volumes were obtained from participating sites for March and April 2020 and compared with those from March 2019. Availability of personal protective equipment and pandemic-related testing practice changes were ascertained. RESULTS Surveys were submitted from 909 inpatient and outpatient centers performing cardiac diagnostic procedures, in 108 countries. Procedure volumes decreased 42% from March 2019 to March 2020, and 64% from March 2019 to April 2020. Transthoradc echocardiography decreased by 59%, transesophageat echocardiography 76%, and stress tests 78%, which varied between stress modalities. Coronary angiography (invasive or computed tomography) decreased 55% (p < 0.001 for each procedure). hi multivariable regression, significantly greater reduction in procedures occurred for centers in countries with lower gross domestic product. Location in a low-income and lower-middle-income country was associated with an additional 22% reduction in cardiac procedures and less availability of personal protective equipment and teteheatth. CONCLUSIONS COVID-19 was associated with a significant and abrupt reduction in cardiovascular diagnostic testing across the globe, especially affecting the world's economically challenged. Further study of cardiovascular outcomes and COVID-19-related changes in care delivery is warranted. (C) 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
- Published
- 2021
- Full Text
- View/download PDF
8. Radiomics Analysis of [18F]-Fluorodeoxyglucose-Avid Thyroid Incidentalomas Improves Risk Stratification and Selection for Clinical Assessment
- Author
-
Luca Ceriani, Pierpaolo Trimboli, Camilla Virili, Luca Giovanella, Lisa Milan, Gaetano Paone, and Luciano Cascione
- Subjects
thyroid incidentaloma ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,chemical and pharmacologic phenomena ,030209 endocrinology & metabolism ,Computed tomography ,predictive model ,Lesion ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Radiomics ,medicine ,Selection (genetic algorithm) ,Fluorodeoxyglucose ,medicine.diagnostic_test ,business.industry ,Thyroid ,[18F]FDG-PET-CT ,medicine.anatomical_structure ,radiomics ,Positron emission tomography ,PET metrics ,030220 oncology & carcinogenesis ,Risk stratification ,Radiology ,medicine.symptom ,business ,medicine.drug - Abstract
Background: [18F]-Fluorodeoxyglucose (FDG)-avid thyroid lesions incidentally detected on positron emission tomography/computed tomography (PET/CT) scans represent a tumor lesion in about 30% of cas...
- Published
- 2021
- Full Text
- View/download PDF
9. Clinical performance of calcitonin and procalcitonin Elecsys® immunoassays in patients with medullary thyroid carcinoma
- Author
-
Frederik A. Verburg, Martina Fontana, Luca Giovanella, Luca Ceriani, Franco Keller, and Radiology & Nuclear Medicine
- Subjects
030213 general clinical medicine ,medicine.medical_specialty ,endocrine system diseases ,Clinical Biochemistry ,030204 cardiovascular system & hematology ,Gastroenterology ,Procalcitonin ,Thyroid carcinoma ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Tumor marker ,business.industry ,Thyroid disease ,Biochemistry (medical) ,Thyroid ,General Medicine ,respiratory system ,medicine.disease ,digestive system diseases ,medicine.anatomical_structure ,Calcitonin ,Biomarker (medicine) ,Differential diagnosis ,business ,circulatory and respiratory physiology - Abstract
Objectives Medullary thyroid carcinoma (MTC) is caused by a malignant transformation in the parafollicular C-cells of the thyroid, where calcitonin (CT) is released. Nowadays, CT is the main tumor marker used in the diagnosis and follow-up of MTC patients. Nonetheless, procalcitonin (PCT) has recently been proposed as a useful complementary/alternative biomarker in MTC. Our aims were to investigate the diagnostic performance of CT and PCT and their combination in the differential diagnosis between active and inactive MTC and between MTC and non-MTC thyroid diseases, respectively. Methods Serum samples were collected from 16 patients with active (i.e. primary tumour before surgery or post-surgical recurrent disease) and 23 with inactive (i.e. complete remission) MTC, 125 patients with non-MTC benign thyroid disease and 62 patients with non-MTC thyroid cancers, respectively. Elecsys® CT and PCT measurements were simultaneously performed on the Cobas e601 platform (Roche Diagnostics, Rotkreutz, Switzerland). Results Both CT and PCT median values in active MTC (94 pmol/L and 1.17 ng/mL, respectively) were significantly higher compared with inactive MTC (0.28 and 0.06) and either benign (0.37 and 0.06) or malignant (0.28 and 0.06) non-MTC. Undetectable PCT was found in five non-MTC patients with false positive CT results. Conclusions Elecsys® PCT assay is a highly sensitive and specific alternative MTC marker. At the very least it appears useful in patients with positive CT results as negative PCT values securely exclude active MTC. The availability of both markers on the same automated platform facilitates reflex or reflective strategies to refine the laboratory diagnosis.
- Published
- 2020
- Full Text
- View/download PDF
10. SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model
- Author
-
Alessandro Rambaldi, Alden A. Moccia, Luca Ceriani, Giovanni Martinelli, Stefanie Hayoz, Luciano Cascione, Luca Giovanella, Anastasios Stathis, Christoph Mamot, Stefan Dirnhofer, Sämi Schär, Angela Polino, Giuseppe Gritti, Andrea Bruno, Maria Cristina Pirosa, Emanuele Zucca, and Teresa Ruberto
- Subjects
0301 basic medicine ,Oncology ,Vincristine ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Hazard ratio ,Hematology ,medicine.disease ,Confidence interval ,03 medical and health sciences ,Regimen ,030104 developmental biology ,0302 clinical medicine ,Positron emission tomography ,Prednisone ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Rituximab ,business ,Diffuse large B-cell lymphoma ,medicine.drug - Abstract
Several functional parameters from baseline (18)F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography have been proposed as promising biomarkers of treatment efficacy in diffuse large B-cell lymphoma (DLBCL). We tested their ability to predict outcome in 2 cohorts of DLBCL patients receiving conventional immunochemotherapy (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone [R-CHOP] regimen), either every 14 (R-CHOP14) or 21 days (R-CHOP21). Baseline PET analysis was performed in 141 patients with DLBCL treated with R-CHOP14 in the prospective SAKK38/07 study (NCT00544219) of the Swiss Group for Clinical Cancer Research (testing set). Reproducibility was examined in a validation set of 113 patients treated with R-CHOP21. In the SAKK38/07 cohort, progression-free survival (PFS) at 5 years was 83% for patients with low metabolic tumor volume (MTV) and 59% for those with high MTV (hazard ratio [HR], 3.4; 95% confidence interval [CI], 1.6-7.0; P = .0005), whereas overall survival (OS) was 91% and 64%, respectively (HR, 4.4; 95% CI, 1.9-10; P = .0001). MTV was the most powerful predictor of outcome also in the validation set. Elevated metabolic heterogeneity (MH) significantly predicted poorer outcomes in the subgroups of patients with elevated MTV. A model integrating MTV and MH identified high-risk patients with shorter PFS (testing set: HR, 5.6; 95% CI, 1.8-17; P < .0001; validation set: HR, 5.6; 95% CI, 1.7-18; P = .0002) and shorter OS (testing set: HR, 9.5; 95% CI, 1.7-52; P < .0001; validation set: HR, 7.6; 95% CI, 2.0-28; P = .0003). This finding was confirmed by an unsupervised regression tree analysis indicating that prognostic models based on MTV and MH may allow early identification of refractory patients who might benefit from treatment intensification. This trial was registered at www.clinicaltrials.gov as #NCT00544219.
- Published
- 2020
- Full Text
- View/download PDF
11. Sciatic pain by neurolymphomatosis as initial presentation of disseminated diffuse large B cell lymphoma involving the testis and the CNS
- Author
-
Esteban Ciliberti, Georg Stussi, Emanuele Zucca, Luca Ceriani, and Davide Facchinelli
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Oncology ,business.industry ,medicine ,Hematology ,General Medicine ,Presentation (obstetrics) ,medicine.disease ,business ,Diffuse large B-cell lymphoma ,Lymphoma - Published
- 2020
- Full Text
- View/download PDF
12. Is thyroglobulin a reliable biomarker of differentiated thyroid cancer in patients treated by lobectomy? A systematic review and meta-analysis
- Author
-
Luca Giovanella, Luca Ceriani, and Maria Luisa Garo
- Subjects
Biochemistry (medical) ,Clinical Biochemistry ,Thyroidectomy ,Humans ,Reproducibility of Results ,General Medicine ,Thyroid Neoplasms ,Adenocarcinoma ,Neoplasm Recurrence, Local ,Thyroglobulin ,Biomarkers ,Retrospective Studies - Abstract
Objectives The prognostic role of thyroglobulin in predicting recurrence in differentiated thyroid cancer (DTC) patients treated by lobectomy is controversial. This systematic review with meta-analysis aimed to update the current evidence deepening the reliability of circulating thyroglobulin in assessing the early response and in predictive recurrence. Methods The methodology was registered in the PROSPERO database under the protocol number CRD42021288189. A systematic search was carried out on PubMed, Embase, Web of Science, and Scopus from September to November 2021 without time and language restrictions. The literature search strategy was based on the following keywords: Thyroglobulin AND (Lobectomy OR Hemithyroidectomy). Results After screening 273 articles, seven studies were included in the systematic review, and only six of them were included in the meta-analysis for a total of 2,455 patients. Circulating thyroglobulin was found non-reliable in assessing early response and predicting recurrence in patients with hemithyroidectomy, especially those with a low initial ATA classification. Conclusions Our study does not support serum thyroglobulin levels for monitoring patients with low-risk DTC treated with lobectomy, and weak evidence supports its role for intermediate- or high-risk patients. Studies with longer follow-up, different study designs, and stringent inclusion/exclusion criteria are needed to evaluate the role of thyroglobulin in recurrence prediction.
- Published
- 2022
13. HL-370 Fragmentóme Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma
- Author
-
Lodovico Terzi di Bergamo, Maria Cristina Pirosa, Alessio Bruscaggin, Matin Salehi, Valeria Spina, Katia Pini, Simone Bocchetta, Claudia Giordano, Adalgisa Condouci, Gabriela Forestieri, Deborah Piffaretti, Joyce Marques de Almeida, Salvatore Annunziata, Fabrizio Bergesio, Eugenio Borsatti, Pietro Bulian, Stephane Chauvie, Marco Cuzzocrea, Martina Di Trani, Bernhard Gerber, Michal Kurlapski, Alden Moccia, Riccardo Moia, Andrea Rinaldi, Marcello Rodari, Grzegorz Romanowicz, Gian Mauro Sacchetti, Alessandra Stasia, Anastasios Stathis, Georg Stuessi, Ilaria Zangrilli, Luigi Maria Larocca, Antonello Pinto, Armando Santoro, Franco Cavalli, Emanuele Zucca, Valter Gattei, Jan Maciej Zaucha, Carmelo Carlo Stella, Stefan Hohaus, Gianluca Gaidano, Luca Ceriani, and Davide Rossi
- Subjects
Cancer Research ,Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
14. PET imaging of lymphomas
- Author
-
Luca Ceriani and Emanuele Zucca
- Subjects
business.industry ,Medicine ,Pet imaging ,business ,Nuclear medicine - Published
- 2022
- Full Text
- View/download PDF
15. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
- Author
-
Anastasios Stathis, Ulrich Mey, Sämi Schär, Felicitas Hitz, Christiane Pott, Nicolas Mach, Fatime Krasniqi, Urban Novak, Christian Schmidt, Karin Hohloch, Dirk Lars Kienle, Dagmar Hess, Alden A. Moccia, Michael Unterhalt, Katrin Eckhardt, Stefanie Hayoz, Gabriela Forestieri, Davide Rossi, Stefan Dirnhofer, Luca Ceriani, Giulio Sartori, Francesco Bertoni, Christian Buske, Emanuele Zucca, and Wolfgang Hiddemann
- Subjects
Sulfonamides ,Treatment Outcome ,Positron Emission Tomography Computed Tomography ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Hematology ,Antibodies, Monoclonal, Humanized ,Bridged Bicyclo Compounds, Heterocyclic ,610 Medicine & health ,Lymphoma, Follicular - Abstract
This phase 1 study evaluated safety, tolerability, and preliminary efficacy of obinutuzumab in combination with venetoclax in patients with previously untreated grade 1-3a follicular lymphoma in need of systemic therapy. Two DLs of venetoclax were evaluated with an expansion cohort at the recommended phase 2 dose. Twenty-five patients were enrolled. The recommended phase 2 dose was venetoclax 800 mg OD continuously for 6 cycles starting on day 2 of cycle 1, with obinutuzumab 1000 mg on days 1, 8, and 15 of cycle 1 and on day 1 of cycles 2 to 6, followed by obinutuzumab maintenance every 2 months for 2 years. Only 1 patient had a DLT consisting of grade 4 thrombocytopenia after the first obinutuzumab infusion. Neutropenia was the most common adverse event of grade ≥3 at least possibly attributed to study treatment. Twenty-four patients were evaluable for response after cycle 6 by computed tomography (CT) and 19 by positron emission tomography/CT (PET/CT): overall and complete response rates were 87.5% (95% CI, 67.6% to 97.3%) and 25% (95% CI, 9.8% to 46.7%) in the CT-evaluated patients and 84.2% (95% CI, 60.4% to 96.6%) and 68.4% (95% CI, 43.4% to 87.4%), respectively, in the PET/CT-evaluated patients. One-year progression-free survival was 77.8% (95% CI, 54.6% to 90.1%) and 79% (95% CI, 47.9% to 92.7%) for CT and PET/CT-evaluable patients, respectively, whereas progression-free survival at 30 months was 73.2% (95% CI, 49.8%, 87.0%) as assessed by CT and 79.0% (95% CI, 47.9%, 92.7%) by PET/CT. Despite the activity observed, our results do not support further development of the combination in this patient population. This trial was registered at www.clinicaltrials.gov as #NCT02877550.
- Published
- 2022
- Full Text
- View/download PDF
16. Radiomics in Malignant Lymphomas
- Author
-
Stephane Chauvie, Luca Ceriani, and Emanuele Zucca
- Published
- 2021
- Full Text
- View/download PDF
17. Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study
- Author
-
Sofia Genta, Guido Ghilardi, Luciano Cascione, Darius Juskevicius, Alexandar Tzankov, Sämi Schär, Lisa Milan, Maria Cristina Pirosa, Fabiana Esposito, Teresa Ruberto, Luca Giovanella, Stefanie Hayoz, Christoph Mamot, Stefan Dirnhofer, Emanuele Zucca, and Luca Ceriani
- Subjects
Cancer Research ,Oncology ,PET/CT ,mutational profile ,DLBCL ,lymphoma ,prognostic index - Abstract
Accurate estimation of the progression risk after first-line therapy represents an unmet clinical need in diffuse large B-cell lymphoma (DLBCL). Baseline (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) parameters, together with genetic analysis of lymphoma cells, could refine the prediction of treatment failure. We evaluated the combined impact of mutation profiling and baseline PET/CT functional parameters on the outcome of DLBCL patients treated with the R-CHOP14 regimen in the SAKK38/07 clinical trial (NCT00544219). The concomitant presence of mutated SOCS1 with wild-type CREBBP and EP300 defined a group of patients with a favorable prognosis and 2-year progression-free survival (PFS) of 100%. Using an unsupervised recursive partitioning approach, we generated a classification-tree algorithm that predicts treatment outcomes. Patients with elevated metabolic tumor volume (MTV) and high metabolic heterogeneity (MH) (15%) had the highest risk of relapse. Patients with low MTV and favorable mutational profile (9%) had the lowest risk, while the remaining patients constituted the intermediate-risk group (76%). The resulting model stratified patients among three groups with 2-year PFS of 100%, 82%, and 42%, respectively (p < 0.001).
- Published
- 2021
- Full Text
- View/download PDF
18. CT evaluation of lung infiltrates in the two months preceding the Coronavirus disease 19 pandemic in Canton Ticino (Switzerland): were there suspicious cases before the official first case?
- Author
-
Stefania Rizzo, Carola Catanese, Carla Puligheddu, Samantha Epistolio, Giulia Ramelli, Milo Frattini, Ricardo Pereira Mestre, Navarajah Nadarajah, Ermidio Rezzonico, Francesco Magoga, Lisa Milan, Filippo Del Grande, Luca Giovanella, and Luca Ceriani
- Subjects
COVID-19 ,Humans ,Radiology, Nuclear Medicine and imaging ,General Medicine ,Tomography, X-Ray Computed ,Lung ,Pandemics ,Switzerland ,Retrospective Studies - Abstract
Purpose The main objective of this study was to assess the presence of pulmonary infiltrates with computed tomography (CT) appearance compatible with infection by coronavirus disease 2019 (COVID-19), in Canton Ticino in the 2 months preceding the first official case. Secondary aims were to compare the classification of infiltrates in the same time frame in 2020 and 2019; to compare the number of chest CT scans in the same period; to search for pathological confirmation of the virus. Materials and methods Chest CT scans performed between January 1 and February 24 in 2019 and 2020 were collected and classified by COVID-19 Reporting and Data System (CO-RADS). Pathological presence of the virus was searched for when appropriate material was available. Results The final cohort included 881 patients. Among the CO-RADS 3 and 4 categories, 30 patients had pneumonitis of unknown etiology. Pathological specimens were available in six patients but they were negative for COVID-19. Conclusion Before the first official case of COVID-19 infection, in Canton Ticino there were about 30 cases of pneumonitis of uncertain origin, with CT appearance compatible with infection by COVID-19, but with no confirmation of the disease. The number of chest CT scans in the first two months of 2020 was > 12% compared to 2019.
- Published
- 2021
19. CLINICAL TRIAL QUALIFICATION OF PET-CT SCANNERS IN ONCO-HAEMATOLOGICAL CLINICAL TRIALS: A WORLDWIDE EXPERIENCE FROM CUNEO IMAGING CORELAB
- Author
-
Fabrizio Bergesio, Adriano De Maggi, Guerra Luca, Monica Coronado, Jan Maciej Zaucha, Luca Ceriani, and Stèphane Chauvie
- Subjects
Biophysics ,General Physics and Astronomy ,Radiology, Nuclear Medicine and imaging ,General Medicine - Published
- 2022
- Full Text
- View/download PDF
20. An Evanishing Thyroid During Immune Checkpoint Inhibitor Therapy
- Author
-
Luca Ceriani, Marco Cuzzocrea, Gaetano Paone, and Luca Giovanella
- Subjects
Oncology ,Adult ,Male ,endocrine system ,medicine.medical_specialty ,Thyroiditis ,endocrine system diseases ,medicine.medical_treatment ,Internal medicine ,Positron Emission Tomography Computed Tomography ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Immune Checkpoint Inhibitors ,business.industry ,Thyroid disease ,Thyroid ,General Medicine ,Immunotherapy ,medicine.disease ,Immune checkpoint ,medicine.anatomical_structure ,Nivolumab ,business ,Chemoradiotherapy ,Hormone - Abstract
In recent years, a large number of articles have described the endocrine-related adverse events associated with immune checkpoint inhibitors, especially affecting the thyroid. A 37-year-old man affected by nasopharyngeal carcinoma (stage IVb) underwent serial 18F-FDG PET/CT evaluations during treatment with nivolumab (480 mg every 4 weeks) after first-line chemoradiotherapy. The patient had no history of thyroid disease and before starting immunotherapy the thyroid-stimulating hormone value was normal at 0.9 mU/L (reference range, 0.27-4.2 mIU/L). FDG PET/CT studies revealed involution of the thyroid gland following immune checkpoint inhibitor-induced thyroiditis.
- Published
- 2021
21. Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis
- Author
-
Emanuele Zucca, F. Esposito, Stephan Dirnhofer, Luciano Cascione, Luca Ceriani, Luca Giovanella, Sämi Schär, Christoph Mamot, Giuseppe Gritti, Federico Dalmasso, Maria Cristina Pirosa, Stephane Chauvie, Andrea Bruno, Alessandro Rambaldi, Stefanie Hayoz, and Lisa Milan
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Radiomics ,Fluorodeoxyglucose F18 ,Internal medicine ,Positron Emission Tomography Computed Tomography ,Post-hoc analysis ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Cyclophosphamide ,Aged ,Retrospective Studies ,Clinical Trials as Topic ,medicine.diagnostic_test ,Proportional hazards model ,business.industry ,Area under the curve ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Clinical trial ,Survival Rate ,Positron emission tomography ,Vincristine ,Cohort ,Prednisone ,Female ,Lymphoma, Large B-Cell, Diffuse ,Radiopharmaceuticals ,business ,Rituximab ,Diffuse large B-cell lymphoma ,Follow-Up Studies - Abstract
Functional parameters from positron emission tomography (PET) seem promising biomarkers in various lymphoma subtypes. This study investigated the prognostic value of PET radiomics in diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP given either every 14 (testing set) or 21 days (validation set). Using the PyRadiomics Python package, 107 radiomics features were extracted from baseline PET scans of 133 patients enrolled in the Swiss Group for Clinical Cancer Research 38/07 prospective clinical trial (SAKK 38/07) [ClinicalTrial.gov identifier: NCT00544219]. The international prognostic indices, the main clinical parameters and standard PET metrics, together with 52 radiomics uncorrelated features (selected using the Spearman correlation test) were included in a least absolute shrinkage and selection operator (LASSO) Cox regression to assess their impact on progression-free (PFS), cause-specific (CSS), and overall survival (OS). A linear combination of the resulting parameters generated a prognostic radiomics score (RS) whose area under the curve (AUC) was calculated by receiver operating characteristic analysis. The RS efficacy was validated in an independent cohort of 107 DLBCL patients. LASSO Cox regression identified four radiomics features predicting PFS in SAKK 38/07. The derived RS showed a significant capability to foresee PFS in both testing (AUC, 0.709; p
- Published
- 2021
22. Author response for 'Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis'
- Author
-
Emanuele Zucca, Stefanie Hayoz, Andrea Bruno, F. Esposito, Luca Ceriani, Alessandro Rambaldi, Stephan Dirnhofer, S. Chauvie, Sämi Schär, Luciano Cascione, Lisa Milan, Federico Dalmasso, Maria Cristina Pirosa, Christoph Mamot, Luca Giovanella, and Giuseppe Gritti
- Subjects
Oncology ,medicine.medical_specialty ,Radiomics ,business.industry ,Internal medicine ,Post-hoc analysis ,medicine ,medicine.disease ,business ,Diffuse large B-cell lymphoma - Published
- 2021
- Full Text
- View/download PDF
23. Role of18F-Choline Positron Emission Tomography/Computed Tomography to Detect Structural Relapse in High-Risk Differentiated Thyroid Cancer Patients
- Author
-
Martina Bruzzone, Gaetano Paone, Giorgio Treglia, Pierpaolo Trimboli, Matteo Puntoni, Arnoldo Piccardo, Mehrdad Naseri, Michela Massollo, Ugo Catrambone, Giulia Ferrarazzo, Luca Ceriani, Gianluca Bottoni, Anselmo Arlandini, Simona Sola, Luca Foppiani, Manlio Cabria, and Luca Giovanella
- Subjects
PET-CT ,High risk patients ,medicine.diagnostic_test ,business.industry ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Computed tomography ,medicine.disease ,18F-choline ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Positron emission tomography ,030220 oncology & carcinogenesis ,Medicine ,business ,Nuclear medicine ,Thyroid cancer ,Positron Emission Tomography-Computed Tomography - Abstract
Background: This study aimed to evaluate the role of 18F-choline (18F-FCH) positron emission tomography (PET)/computed tomography (CT) in high-risk differentiated thyroid cancer (DTC) patients with...
- Published
- 2019
- Full Text
- View/download PDF
24. Fine-needle aspiration to diagnose primary thyroid lymphomas: a systematic review and meta-analysis
- Author
-
Luca Ceriani, Luca Giovanella, Marco Castellana, Lu Zhang, Francesco Giorgino, Pierpaolo Trimboli, Camilla Virili, Emanuele Zucca, Anna Crescenzi, and Franco Cavalli
- Subjects
medicine.medical_specialty ,primary thyroid lymphoma ,cytology ,FNA ,Endocrinology, Diabetes and Metabolism ,MEDLINE ,030209 endocrinology & metabolism ,Malignancy ,Thyroid carcinoma ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Thyroid lymphoma ,Internal medicine ,medicine ,medicine.diagnostic_test ,business.industry ,General Medicine ,Gold standard (test) ,Publication bias ,medicine.disease ,Fine-needle aspiration ,030220 oncology & carcinogenesis ,Meta-analysis ,embryonic structures ,Radiology ,business - Abstract
Background Primary thyroid lymphoma (PTL) is a rare malignancy, and its prognosis depends significantly on its early diagnosis. While fine-needle aspiration (FNA) represents the gold standard to identify differentiated thyroid carcinoma, its reliability for the detection of PTL is still unclear. Here, we conducted a systematic review and meta-analysis to evaluate the diagnostic performance of FNA in PTL. Research design and methods A comprehensive literature search of PubMed/MEDLINE and Scopus databases was conducted to retrieve papers reporting histologically proven PTL undergone FNA. The last search was performed in February 2018 without language and time restrictions. Results Thirty-two studies describing 593 PTL were included and the pooled FNA sensitivity was 0.48 (95% CI = 0.38–0.58). FNA sensitivity was 0.51 in 20 studies published before 2010 and 0.39 in those published later, 0.50 in six articles with at least 20 cases and 0.44 in nine series enrolled after 2000. This performance was similar in 12 articles including diffuse large B-cell lymphoma (0.54) and those six on marginal zone lymphoma (0.56). Remarkably, FNA sensitivity increased to 0.72 when considering also FNA reports suspicious for PTL reported in 14 articles. Heterogeneity among the series was found. Publication bias was not always detected. Conclusions The present meta-analysis demonstrated that FNA has low sensitivity in diagnosing PTL. However, this rate increased when considering also FNA reports suspicious for PTL, which is relevant from a clinical standpoint. This result could support indirectly the use of additional imaging and/or core biopsy when PTL is suspected.
- Published
- 2019
- Full Text
- View/download PDF
25. Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume
- Author
-
Stefano Presilla, Luca Ceriani, Maurizio Martelli, Luca Giovanella, Peter Johnson, Lisa Milan, and Emanuele Zucca
- Subjects
Risk ,Lymphoma, B-Cell ,Lymphoma ,Metabolic tumour volume ,Mediastinal Neoplasms ,Disease-Free Survival ,Imaging phantom ,Imaging ,030218 nuclear medicine & medical imaging ,Correlation ,03 medical and health sciences ,0302 clinical medicine ,Fluorodeoxyglucose F18 ,Predictive Value of Tests ,parasitic diseases ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,medicine.diagnostic_test ,Phantoms, Imaging ,business.industry ,Disease progression ,General Medicine ,Prognosis ,medicine.disease ,Predictive value ,Tumor Burden ,Positron-emission tomography ,PET metrics ,Positron emission tomography ,030220 oncology & carcinogenesis ,Risk stratification ,Tumour volume ,Primary mediastinal B-cell lymphoma ,Nuclear medicine ,business ,Algorithms ,Software - Abstract
This study assessed the performance of four different methods for the estimation of metabolic tumour volume (MTV) in primary mediastinal B cell lymphoma (PMBCL). MTV was estimated using either a region growing automatic software program (RG) or a fixed threshold (FT) segmentation algorithm with the three most common cut-offs proposed in the literature (i.e., 25% and 41% of the SUVmax and SUV value ≥2.5). We compared these four methods using phantoms that simulated different set-ups of the main imaging characteristics of PMBCL (volume, shape, 18-FDG uptake and intra-lesion distribution) and assessed their performance in 103 PMBCL patients enrolled in the International Extranodal Lymphoma Study Group-26 (IELSG-26) study. There was good correlation between MTV values estimated in vitro and in vivo using the different methods. The 25% FT cut-off (FT25%) provided the most accurate MTV evaluation in the phantoms. The cut-off at SUV 2.5 (FT2.5) resulted in MTV overestimation that particularly increased with high SUV values. The 41% cut-off (FT41%) showed MTV underestimation that was more evident when there were high levels of heterogeneity in tracer distribution. Shape of the lesion did not affect MTV computation. The RG algorithm provided a systematic slight MTV underestimation without significant changes due to lesion characteristics. We observed analogous trends for the MTV estimation in patients, with very different derived thresholds for the four methods. Optimal cut-offs for predicting progression-free survival (PFS) ranged from 213 to 831 ml. All methods predicted PFS with similar negative predictive values (94–95%) but different positive predictive values (23–45%). The different methods result in significantly different MTV cut-off values. All allow risk stratification in PMBCL, but FT25% showed the best capacity to predict disease progression in the patient cohort and provided the best accuracy in the phantom model.
- Published
- 2019
- Full Text
- View/download PDF
26. Poster: HL-370 Fragmentome Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma
- Author
-
Lodovico Terzi di Bergamo, Maria Cristina Pirosa, Alessio Bruscaggin, Matin Salehi, Valeria Spina, Katia Pini, Simone Bocchetta, Claudia Giordano, Adalgisa Condouci, Gabriela Forestieri, Deborah Piffaretti, Joyce Marques de Almeida, Salvatore Annunziata, Fabrizio Bergesio, Eugenio Borsatti, Pietro Bulian, Stephane Chauvie, Marco Cuzzocrea, Martina Di Trani, Bernhard Gerber, Michal Kurlapski, Alden Moccia, Riccardo Moia, Andrea Rinaldi, Marcello Rodari, Grzegorz Romanowicz, Gian Mauro Sacchetti, Alessandra Stasia, Anastasios Stathis, Georg Stuessi, Ilaria Zangrilli, Luigi Maria Larocca, Antonello Pinto, Armando Santoro, Franco Cavalli, Emanuele Zucca, Valter Gattei, Jan Maciej Zaucha, Carmelo Carlo Stella, Stefan Hohaus, Gianluca Gaidano, Luca Ceriani, and Davide Rossi
- Subjects
Cancer Research ,Oncology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
27. Procalcitonin as an Alternative Tumor Marker of Medullary Thyroid Carcinoma
- Author
-
Maria Luisa Garo, Gaetano Paone, Federica D'Aurizio, Luca Giovanella, Alfredo Campennì, and Luca Ceriani
- Subjects
medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Clinical Biochemistry ,Context (language use) ,Biochemistry ,Gastroenterology ,Procalcitonin ,Endocrinology ,medullary thyroid carcinoma ,Positive predicative value ,Internal medicine ,calcitonin ,Biomarkers, Tumor ,Medicine ,Humans ,Thyroid Neoplasms ,Tumor marker ,meta-analysis ,procalcitonin ,Receiver operating characteristic ,business.industry ,Biochemistry (medical) ,Area under the curve ,Prognosis ,Carcinoma, Neuroendocrine ,ROC Curve ,Calcitonin ,Meta-analysis ,business - Abstract
Context Calcitonin (CT) measurement is pivotal in the management of medullary thyroid carcinoma (MTC), but several pitfalls can affect its reliability. Procalcitonin (ProCT) has been reported as a promising alternative MTC tumor marker. Objective This study aimed to determine the ProCT diagnostic accuracy in prediction and treatment monitoring of MTC. Methods Electronic databases were searched for observational studies published until May 2021 without language or time restrictions. Studies comparing ProCT and calcitonin accuracy were included. After removing duplicates and exclusion of not-eligible articles, relevant articles were screened independently by 2 reviewers. Eleven studies (4.5% of the identified studies) met the selection criteria. Two reviewers independently extracted data and assessed data quality and validity through QUADAS-2. Results A meta-analysis was performed on 11 sufficiently clinically and statistically homogeneous studies (n = 5817 patients, 335 MTC patients). Hierarchical summary receiver operating characteristics and bivariate methods were applied. Serum ProCT was found to be a highly accurate test for MTC diagnosis and monitoring. The pooled sensitivity, specificity, positive and negative likelihood ratios, area under the curve, and positive and negative predictive values for ProCT were 0.90 (95% CI: 0.71-0.97), 1.00 (95% CI: 0.85-1.00), 288 (95% CI: 5.6-14 929.3), 0.10 (95% CI: 0.03-0.33), 0.97 (95% CI: 0.95-0.98), 99%, and 2%, respectively. Conclusions The high accuracy, compounded with favorable analytical characteristics, give ProCT great potential to replace calcitonin as a new standard of care in the management of MTC.
- Published
- 2021
28. DEVELOPMENT AND VALIDATION OF A PET RADIOMICS PROGNOSTIC MODEL FOR DIFFUSE LARGE B CELL LYMPHOMA
- Author
-
Luciano Cascione, Stefan Dirnhofer, Andrea Bruno, Luca Giovanella, F. Esposito, Giuseppe Gritti, Federico Dalmasso, Lisa Milan, Alessandro Rambaldi, S. Chauvie, Christoph Mamot, Stefanie Hayoz, Emanuele Zucca, Säm Schär, and Luca Ceriani
- Subjects
Cancer Research ,Oncology ,Radiomics ,business.industry ,Prognostic model ,Cancer research ,Medicine ,Hematology ,General Medicine ,business ,medicine.disease ,Diffuse large B-cell lymphoma - Published
- 2021
- Full Text
- View/download PDF
29. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA
- Author
-
D. Piffaretti, Manuela Mollejo, L. Terzi di Bergamo, M. G. Cittone, Liliana Devizzi, Guido Ghilardi, Estella Matutes, Elena Sabattini, Elisa Lucchini, Sílvia Beà, Lydia Scarfò, Sergio Cogliatti, Stefano Pileri, Davide Rossi, M. Án. Piris, Govind Bhagat, Gilles Salles, Armando López-Guillermo, Maria Joao Baptista, Emanuele Zucca, Alden A. Moccia, Alessandra Tucci, Vincenzo Canzonieri, M. Ladetto, Luca Arcaini, Renzo Boldorini, Gabriela Forestieri, Maria Cristina Pirosa, Elias Campo, Alessandro Broccoli, Thomas Tousseyn, Sascha Dietrich, Roberto Marasca, Gianluca Gaidano, Ricardo Koch, Enrico Derenzini, Fabio Facchetti, Juan F. García, Alexandar Tzankov, Michele Merli, Carlo Visco, Hossein Khiabanian, Francesca Guidetti, Franco Cavalli, Arianna Calcinotto, Francesco Passamonti, Thorsten Zenz, Giuseppe Gritti, Julia T. Geyer, Marco Lucioni, M. Ponzoni, M. Faderl, Francesco Bertoni, Anastasios Stathis, Antonino Maiorana, Urban Novak, L. de Leval, Alexandra Traverse-Glehen, Luca Mazzucchelli, Anna Guidetti, Gabriela Bastidas, Véronique Meignin, P. L. Zinzani, Luciano Cascione, Ferdinando Bonfiglio, Giorgio Inghirami, Felicitas Hitz, Stefano Pizzolitto, Alberto J. Arribas, Angela Rita Elia, Elisa Santambrogio, Georg Stussi, Catherine Thieblemont, David Oscier, Marco Paulli, Bernhard Gerber, Umberto Vitolo, Alessio Bruscaggin, Francesco Piazza, Stefan Dirnhofer, W. Wu, Paolo Ghia, Valeria Spina, L. Bonomini, K. Pini, Gustavo Tapia, M. G. Da Silva, Luca Ceriani, Carlos Montalbán, and Adalgisa Condoluci
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Oncology ,medicine ,Hematology ,General Medicine ,Splenic marginal zone lymphoma ,Biology ,medicine.disease ,Phenotype - Published
- 2021
- Full Text
- View/download PDF
30. CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC HODGKIN LYMPHOMA
- Author
-
Bernhard Gerber, Jan Maciej Zaucha, A. Stasia, E. Borsatti, Carmelo Carlo-Stella, Alessio Bruscaggin, Valeria Spina, Salvatore Annunziata, Anastasios Stathis, M. Kurlapski, F. Cavalli, Alden A. Moccia, Luca Ceriani, Gabriela Forestieri, G. Romanowicz, D. Rossi, Antonello Pinto, Ricardo Koch, Gian Mauro Sacchetti, Gianluca Gaidano, Georg Stussi, Adalgisa Condoluci, Riccardo Moia, S. Chauvie, M. Faderl, Maria Cristina Pirosa, I. Zangrilli, S. Hohaus, K. Pini, S. Gillessen Sommer, M. G. Cittone, Pietro Bulian, M. di Trani, Emanuele Zucca, Marcello Rodari, D. Piffaretti, L. Terzi di Bergamo, and V. Gattei
- Subjects
Cancer Research ,Oncology ,Circulating tumor DNA ,business.industry ,Cancer research ,Hodgkin lymphoma ,Medicine ,Prognostic biomarker ,Hematology ,General Medicine ,business - Published
- 2021
- Full Text
- View/download PDF
31. INTEGRATION OF BASELINE METABOLIC PARAMETERS AND MUTATIONAL PROFILE PREDICTS OUTCOME IN DLBCL PATIENTS. A POST HOC ANALYSIS OF SAKK38/07 STUDY
- Author
-
Alexandar Tzankov, Luca Giovanella, Emanuele Zucca, Luca Ceriani, Stefan Dirnhofer, G Ghilardi, S Genta, Sämi Schär, Stefanie Hayoz, Darius Juskevicius, Christoph Mamot, and Luciano Cascione
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Internal medicine ,Post-hoc analysis ,Medicine ,Hematology ,General Medicine ,Baseline (configuration management) ,business ,Outcome (game theory) - Published
- 2021
- Full Text
- View/download PDF
32. Reduction of cardiac imaging tests during the COVID-19 pandemic: The case of Italy. Findings from the IAEA Non-invasive Cardiology Protocol Survey on COVID-19 (INCAPS COVID)
- Author
-
Dondi, M., Milan, E., Pontone, G., Hirschfeld, C. B., Williams, M., Shaw, L. J., Pynda, Y., Raggi, P., Cerci, R., Vitola, J., Better, N., Villines, T. C., Dorbala, S., Pascual, T. N. B., Giubbini, R., Einstein, A. J., Paez, D., Italy: Domenico Albano, Pierpaolo, Alongi, Gaspare, Arnone, Elisa, Bagatin, Sergio, Baldari, Matteo, Bauckneht, Paolo, Bertelli, Francesco, Bianco, Rachele, Bonfiglioli, Roberto, Boni, Andrea, Bruno, Isabella, Bruno, Elena, Busnardo, Elena, Califaretti, Luca, Camoni, Aldo, Carnevale, Roberta, Casoni, Armando Ugo Cavallo, Giorgio, Cavenaghi, Franca, Chierichetti, Marcello, Chiocchi, Corrado, Cittanti, Mauro, Colletta, Umberto, Conti, Alberto, Cossu, Alberto, Cuocolo, Marco, Cuzzocrea, Maria Luisa De Rimini, Giuseppe De Vincentis, Eleonora Del Giudice, Alberico Del Torto, Veronica Della Tommasina, Rexhep, Durmo, Paola Anna Erba, Laura, Evangelista, Riccardo, Faletti, Evelina, Faragasso, Mohsen, Farsad, Paola, Ferro, Luigia, Florimonte, Viviana, Frantellizzi, Fabio Massimo Fringuelli, Marco, Gatti, Angela, Gaudiano, Alessia, Gimelli, Raffaele, Giubbini, Francesca, Giuffrida, Salvatore, Ialuna, Riccardo, Laudicella, Lucia, Leccisotti, Lucia, Leva, Liga, Riccardo, Carlo, Liguori, Giampiero, Longo, Margherita, Maffione, Maria Elisabetta Mancini, Claudio, Marcassa, Elisa, Milan, Barbara, Nardi, Sara, Pacella, Giovanna, Pepe, Gianluca, Pontone, Sabina, Pulizzi, Natale, Quartuccio, Lucia, Rampin, Fabrizio, Ricci, Pierluigi, Rossini, Giuseppe, Rubini, Vincenzo, Russo, Gian Mauro Sacchetti, Gianmario, Sambuceti, Massimo, Scarano, Roberto, Sciagrà, Massimiliano, Sperandio, Antonella, Stefanelli, Guido, Ventroni, Stefania Zoboli Members from Rest of the World (alphabetically by country and last name) Afghanistan: Mohammad Nawaz Nasery Albania: Artan Goda, Ervina Shirka Algeria: Rabie Benlabgaa, Salah, Bouyoucef, Abdelkader, Medjahedi, Qais Nailli Argentina: Mariela Agolti, Roberto Nicolas Aguero, Maria del Carmen Alak, Lucia Graciela Alberguina, Guillermo, Arroñada, Andrea, Astesiano, Alfredo, Astesiano, Carolina Bas Norton, Pablo, Benteo, Juan, Blanco, Juan Manuel Bonelli, Jose Javier Bustos, Raul, Cabrejas, Jorge, Cachero, Roxana, Campisi, Alejandro, Canderoli, Silvia, Carames, Patrícia, Carrascosa, Ricardo, Castro, Oscar, Cendoya, Luciano Martin Cognigni, Carlos, Collaud, Claudia, Cortes, Javier, Courtis, Daniel, Cragnolino, Mariana, Daicz, Alejandro De La Vega, Silvia Teresa De Maria, Horacio Del Riego, Fernando, Dettori, Alejandro, Deviggiano, Laura, Dragonetti, Mario, Embon, Ruben Emilio Enriquez, Jorge, Ensinas, Fernando, Faccio, Adolfo, Facello, Diego, Garofalo, Ricardo, Geronazzo, Natalia, Gonza, Lucas, Gutierrez, Miguel Angel Guzzo, Victor, Hasbani, Melina, Huerin, Victor, Jäger, Julio Manuel Lewkowicz, Maria Nieves, A López De Munaín, Jose Maria Lotti, Alejandra, Marquez, Osvaldo, Masoli, Osvaldo Horacio Masoli, Edgardo, Mastrovito, Matias, Mayoraz, Graciela Eva Melado, Anibal, Mele, Maria Fernanda Merani, Alejandro Horacio Meretta, Susana, Molteni, Marcos, Montecinos, Eduardo, Noguera, Carlos, Novoa, Claudio Pereyra Sueldo, Sebastian Perez Ascani, Pablo, Pollono, Maria Paula Pujol, Alejandro, Radzinschi, Gustavo, Raimondi, Marcela, Redruello, Marina, Rodríguez, Matías, Rodríguez, Romina Lorena Romero, Arturo Romero Acuña, Federico, Rovaletti, Lucas San Miguel, Lucrecia, Solari, Bruno, Strada, Sonia, Traverso, Sonia Simona Traverzo, Maria del Huerto Velazquez Espeche, Juan Sebastian Weihmuller, Juan, Wolcan, Susana Zeffiro Armenia: Mari Sakanyan Australia: Scott Beuzeville, Raef, Boktor, Patrick, Butler, Jennifer, Calcott, Loretta, Carr, Virgil, Chan, Charles, Chao, Woon, Chong, Mark, Dobson, D'Arne, Downie, Girish, Dwivedi, Barry, Elison, Jean, Engela, Roslyn, Francis, Anand, Gaikwad, Ashok Gangasandra Basavaraj, Bruce, Goodwin, Robert, Greenough, Christian, Hamilton-Craig, Victar, Hsieh, Subodh, Joshi, Karin, Lederer, Kenneth, Lee, Joseph, Lee, John, Magnussen, Nghi, Mai, Gordon, Mander, Fiona, Murton, Dee, Nandurkar, Johanne, Neill, Edward, O'Rourke, Patricia, O'Sullivan, George, Pandos, Kunthi, Pathmaraj, Alexander, Pitman, Rohan, Poulter, Manuja, Premaratne, David, Prior, Lloyd, Ridley, Natalie, Rutherford, Hamid, Salehi, Connor, Saunders, Luke, Scarlett, Sujith, Seneviratne, Deepa, Shetty, Ganesh, Shrestha, Jonathan, Shulman, Vijay, Solanki, Tony, Stanton, Murch, Stuart, Michael, Stubbs, Ian, Swainson, Kim, Taubman, Andrew, Taylor, Paul, Thomas, Steven, Unger, Anthony, Upton, Shankar, Vamadevan, William Van Gaal, Johan, Verjans, Demetrius, Voutnis, Victor, Wayne, Peter, Wilson, David, Wong, Kirby, Wong, John Younger Austria: Gudrun Feuchtner, Siroos, Mirzaei, Konrad Weiss Belarus: Natallia Maroz-Vadalazhskaya Belgium: Olivier Gheysens, Filip, Homans, Rodrigo, Moreno-Reyes, Agnès, Pasquet, Veronique, Roelants, Van De Heyning Bolivia: Raúl Araujo Ríos Bosnia - Herzegovina: Valentina Soldat-Stankovic, Caroline M., Sinisa Stankovic Brazil: Maria Helena Albernaz Siqueira, Augusto, Almeida, Paulo Henrique Alves Togni, Jose Henrique Andrade, Luciana, Andrade, Carlos, Anselmi, Roberta, Araújo, Guilherme, Azevedo, Sabbrina, Bezerra, Rodrigo, Biancardi, Gabriel Blacher Grossman, Simone, Brandão, Diego Bromfman Pianta, Lara, Carreira, Bruno, Castro, Tien, Chang, Fernando Cunali, Jr., Roberto, Cury, Roberto, Dantas, Fernando de Amorim Fernandes, Andrea De Lorenzo, Robson De Macedo Filho, Fernanda, Erthal, Fabio, Fernandes, Juliano, Fernandes, Thiago Ferreira De Souza, Wilson Furlan Alves, Bruno, Ghini, Luiz, Goncalves, Ilan, Gottlieb, Marcelo, Hadlich, Vinícius, Kameoka, Ronaldo, Lima, Adna, Lima, Rafael Willain Lopes, Ricardo Machado, e Silva, Tiago, Magalhães, Fábio Martins Silva, Luiz Eduardo Mastrocola, Fábio, Medeiros, José Claudio Meneghetti, Vania, Naue, Danilo, Naves, Roberto, Nolasco, Cesar, Nomura, Joao Bruno Oliveira, Eduardo, Paixao, Filipe Penna De Carvalho, Ibraim, Pinto, Priscila, Possetti, Mayra, Quinta, Rodrigo Rizzo Nogueira Ramos, Ricardo, Rocha, Alfredo, Rodrigues, Carlos, Rodrigues, Leila, Romantini, Adelina, Sanches, Sara, Santana, Leonardo Sara da Silva, Paulo, Schvartzman, Cristina Sebastião Matushita, Tiago, Senra, Afonso, Shiozaki, Maria Eduarda Menezes de Siqueira, Cristiano, Siqueira, Paola, Smanio, Carlos Eduardo Soares, José Soares Junior, Marcio Sommer Bittencourt, Bernardo, Spiro, Cláudio Tinoco Mesquita, Jorge, Torreao, Rafael, Torres, Marly, Uellendahl, Guilherme Urpia Monte, Otávia, Veríssimo, Estevan Vieira Cabeda, Felipe Villela Pedras, Roberto, Waltrick, Marcello Zapparoli Brunei Darussalam: Hamid Naseer Bulgaria: Marina Garcheva-Tsacheva, Irena Kostadinova Cambodia: Youdaline Theng Canada: Gad Abikhzer, Rene, Barette, Benjamin, Chow, Dominique, Dabreo, Matthias, Friedrich, Ria, Garg, Mohammed Nassoh Hafez, Chris, Johnson, Marla, Kiess, Jonathon, Leipsic, Eugene, Leung, Robert, Miller, Anastasia, Oikonomou, Stephan, Probst, Idan, Roifman, Gary, Small, Vikas, Tandon, Adwait, Trivedi, James, White, Katherine Zukotynski Chile: Jose Canessa, Gabriel Castro Muñoz, Carmen, Concha, Pablo, Hidalgo, Cesar, Lovera, Teresa, Massardo, Luis Salazar Vargas Colombia: Pedro Abad, Harold, Arturo, Sandra, Ayala, Luis, Benitez, Alberto, Cadena, Carlos, Caicedo, Antonio Calderón Moncayo, Sharon, Gomez, Gutierrez Villamil, Claudia T., Claudia, Jaimes, Juan, Londoño, Juan Luis Londoño Blair, Luz, Pabon, Mauricio, Pineda, Juan Carlos Rojas, Diego, Ruiz, Manuel Valencia Escobar, Andres, Vasquez, Damiana, Vergel, Alejandro Zuluaga Costa Rica: Isabel Berrocal Gamboa, Gabriel, Castro, Ulises, González, Croatia: Ana Baric, Tonci, Batinic, Maja, Franceschi, Maja Hrabak Paar, Mladen, Jukic, Petar, Medakovic, Viktor, Persic, Marina, Prpic, Ante Punda Cuba: Juan Felipe Batista, Juan Manuel Gómez Lauchy, Yamile Marcos Gutierrez, Rayner, Menéndez, Amalia, Peix, Luis Rochela Cyprus: Christoforos Panagidis, Ioannis Petrou Czech Republic: Vaclav Engelmann, Milan, Kaminek, Vladimír, Kincl, Otto, Lang, Milan Simanek Denmark: Jawdat Abdulla, Morten, Bøttcher, Mette, Christensen, Lars Christian Gormsen, Philip, Hasbak, Søren, Hess, Paw, Holdgaard, Allan, Johansen, Kasper, Kyhl, Bjarne Linde Norgaard, Kristian Altern Øvrehus, Niels Peter Rønnow Sand, Rolf, Steffensen, Anders, Thomassen, Bo Zerahn Dominican Republic: Alfredo Perez Ecuador: Giovanni Alejandro Escorza Velez, Mayra Sanchez Velez Egypt: Islam Shawky Abdel Aziz, Mahasen, Abougabal, Taghreed, Ahmed, Adel, Allam, Ahmed, Asfour, Mona, Hassan, Alia, Hassan, Ahmed, Ibrahim, Sameh, Kaffas, Ahmed, Kandeel, Mohamed Mandour Ali, Ahmad, Mansy, Hany, Maurice, Sherif, Nabil, Mahmoud Shaaban El Salvador: Ana Camila Flores Estonia: Anne Poksi Finland: Juhani Knuuti, Velipekka, Kokkonen, Martti, Larikka, Valtteri Uusitalo France: Matthieu Bailly, Samuel, Burg, Jean-François, Deux, Vincent, Habouzit, Fabien, Hyafil, Olivier, Lairez, Franck, Proffit, Hamza, Regaieg, Laure, Sarda-Mantel, Schneider Ghana: Harold Ayetey Greece: George Angelidis, Vania Tacher Germany: Roman P., Aikaterini, Archontaki, Sofia, Chatziioannou, Ioannis, Datseris, Christina, Fragkaki, Panagiotis, Georgoulias, Sophia, Koukouraki, Maria, Koutelou, Eleni, Kyrozi, Evangelos, Repasos, Petros, Stavrou, Pipitsa Valsamaki Guatemala: Carla Gonzalez, Goleat Gutierrez Honduras: Alejandro Maldonado Hungary: Klara Buga, Ildiko, Garai, Pál, Maurovich-Horvat, Erzsébet, Schmidt, Balint, Szilveszter, Edit Várady India: Nilesh Banthia, Jinendra Kumar Bhagat, Rishi, Bhargava, Vivek, Bhat, Mona, Bhatia, Partha, Choudhury, Vijay Sai Chowdekar, Aparna, Irodi, Shashank, Jain, Elizabeth, Joseph, Sukriti, Kumar, Prof Dr Girijanandan Mahapatra, Deepanjan, Mitra, Bhagwant Rai Mittal, Ahmad, Ozair, Chetan, Patel, Tapan, Patel, Ravi, Patel, Shivani, Patel, Sudhir, Saxena, Shantanu, Sengupta, Santosh, Singh, Bhanupriya, Singh, Ashwani, Sood, Atul Verma Indonesia: Erwin Affandi, Padma Savenadia Alam, Edison, Edison, Gani, Gunawan, Habusari, Hapkido, Basuki, Hidayat, Aulia, Huda, Anggoro Praja Mukti, Djoko, Prawiro, Erwin Affandi Soeriadi, Hilman Syawaluddin Iraq: Amjed Albadr Islamic Republic of Iran: Majid Assadi, Farshad, Emami, Golnaz, Houshmand, Majid, Maleki, Maryam Tajik Rostami, Seyed Rasoul Zakavi Israel: Eed Abu Zaid, Svetlana, Agranovich, Yoav, Arnson, Rachel, Bar-Shalom, Alex, Frenkel, Galit, Knafo, Rachel, Lugassi, Israel Shlomo Maor Moalem, Maya, Mor, Noam, Muskal, Sara, Ranser, Aryeh Shalev Jamaica: Dainia Baugh, Duane, Chambers, Ernest, Madu, Felix Nunura Japan: Hiroshi Asano, Chimura Misato Chimura, Shinichiro, Fujimoto, Koichiro, Fujisue, Tomohisa, Fukunaga, Yoshimitsu, Fukushima, Kae, Fukuyama, Jun, Hashimoto, Yasutaka, Ichikawa, Nobuo, Iguchi, Masamichi, Imai, Anri, Inaki, Hayato, Ishimura, Satoshi, Isobe, Toshiaki, Kadokami, Takao, Kato, Takashi, Kudo, Shinichiro, Kumita, Hirotaka, Maruno, Hiroyuki, Mataki, Masao, Miyagawa, Ryota, Morimoto, Masao, Moroi, Shigeki, Nagamachi, Kenichi, Nakajima, Tomoaki, Nakata, Ryo, Nakazato, Mamoru, Nanasato, Masanao, Naya, Takashi, Norikane, Yasutoshi, Ohta, Satoshi, Okayama, Atsutaka, Okizaki, Yoichi, Otomi, Hideki, Otsuka, Masaki, Saito, Sakata Yasushi Sakata, Masayoshi, Sarai, Daisuke, Sato, Shinya, Shiraishi, Yoshinobu, Suwa, Kentaro, Takanami, Kazuya, Takehana, Junichi, Taki, Nagara, Tamaki, Yasuyo, Taniguchi, Hiroki, Teragawa, Nobuo, Tomizawa, Kenichi, Tsujita, Kyoko, Umeji, Yasushi, Wakabayashi, Shinichiro, Yamada, Shinya, Yamazaki, Tatsuya Yoneyama Jordan: Mohammad Rawashdeh Kazakhstan: Daultai Batyrkhanov, Tairkhan Dautov Kenya: Khalid Makhdomi, Kevin Ombati Kuwait: Faridah Alkandari, Masoud Garashi Lao People's Democratic Republic: Tchoyoson Lim Coie, Sonexay Rajvong Latvia: Artem Kalinin, Marika Kalnina Lebanon: Mohamad Haidar Lithuania: Renata Komiagiene, Giedre, Kviecinskiene, Mindaugas, Mataciunas, Karim Malta: Luise Reichmuth, Donatas Vajauskas Luxembourg: Christian Picard Malaysia: Noor Khairiah A., Anthony Samuel Mauritius: Mohammad Aaftaab Allarakha, Ambedhkar Shantaram Naojee Mexico: Erick Alexanderson-Rosas, Erika, Barragan, Alejandro Becerril González-Montecinos, Manuel, Cabada, Daniel Calderon Rodriguez, Isabel, Carvajal-Juarez, Violeta, Cortés, Filiberto, Cortés, Erasmo De La Peña, Manlio, Gama-Moreno, Luis, González, Nelsy Gonzalez Ramírez, Moisés, Jiménez-Santos, Luis, Matos, Edgar, Monroy, Martha, Morelos, Mario, Ornelas, Jose Alberto Ortga Ramirez, Andrés, Preciado-Anaya, Óscar Ulises Preciado-Gutiérrez, Adriana Puente Barragan, Sandra Graciela Rosales Uvera, Sigelinda, Sandoval, Miguel Santaularia Tomas, Sierra-Galan, Lilia M., Silvia, Siu, Enrique, Vallejo, Mario Valles Monaco: Marc Faraggi Mongolia: Erdenechimeg Sereegotov Montenegro: Srdja Ilic Morocco: Nozha Ben-Rais, Nadia Ismaili Alaoui, Sara Taleb Myanmar: Khin Pa Pa Myo, Phyo Si Thu Nepal: Ram Kumar Ghimire, Bijoy Rajbanshi Netherlands: Peter Barneveld, Andor, Glaudemans, Jesse, Habets, Klaas Pieter Koopmans, Jeroen, Manders, Stefan, Pool, Arthur, Scholte, Asbjørn, Scholtens, Riemer, Slart, Paul, Thimister, Erik-Jan Van Asperen, Niels, Veltman, Derk, Verschure, Nils Wagenaar New Zealand: John Edmond, Chris, Ellis, Kerryanne, Johnson, Ross, Keenan, Shaw Hua (Anthony) Kueh, Christopher, Occleshaw, Alexander, Sasse, Andrew, To, Niels Van Pelt, Calum Young Nicaragua: Teresa Cuadra, Hector Bladimir Roque Vanegas Niger: Idrissa Adamou Soli, Djibrillou Moussa Issoufou Nigeria: Tolulope Ayodele, Chibuzo, Madu, Yetunde Onimode Norway: Elen Efros-Monsen, Signe Helene Forsdahl, Jenni-Mari Hildre Dimmen, Arve, Jørgensen, Isabel, Krohn, Pål, Løvhaugen, Anders Tjellaug Bråten Oman: Humoud Al Dhuhli, Faiza Al Kindi, Naeema, Al-Bulushi, Zabah, Jawa, Naima Tag Pakistan: Muhammad Shehzad Afzal, Shazia, Fatima, Muhammad Numair Younis, Musab, Riaz, Mohammad Saadullah Panama: Yariela Herrera Papua New Guinea: Dora Lenturut-Katal Paraguay: Manuel Castillo Vázquez, José Ortellado People's Republic of Bangladesh: Afroza Akhter People's Republic of China: Dianbo Cao, Stephen, Cheung, Dai, Xu, Lianggeng, Gong, Dan, Han, Yang, Hou, Caiying, Li, Tao, Li, Dong, Li, Sijin, Li, Jinkang, Liu, Hui, Liu, Bin, Lu, Ming Yen Ng, Kai, Sun, Gongshun, Tang, Jian, Wang, Ximing, Wang, Zhao-Qian, Wang, Yining, Wang, Yifan, Wang, Jiang, Wu, Zhifang, Wu, Liming, Xia, Jiangxi, Xiao, Lei, Xu, Youyou, Yang, Yin, Wu, Jianqun, Yu, Yuan, Li, Tong, Zhang, Longjiang, Zhang, Yong-Gao, Zhang, Xiaoli, Zhang, Li Zhu Peru: Ana Alfaro Philippines: Paz Abrihan, Asela, Barroso, Eric, Cruz, Marie Rhiamar Gomez, Vincent Peter Magboo, John Michael Medina, Jerry, Obaldo, Davidson, Pastrana, Christian Michael Pawhay, Alvin, Quinon, Jeanelle Margareth Tang, Bettina, Tecson, Kristine Joy Uson, Mila Uy Poland: Magdalena Kostkiewicz, Jolanta Kunikowska Portugal: Nuno Bettencourt, Guilhermina, Cantinho, Antonio Ferreira Qatar: Ghulam Syed Republic of Ireland: Samer Arnous, Said, Atyani, Angela, Byrne, Tadhg, Gleeson, David, Kerins, Conor, Meehan, David, Murphy, Mark, Murphy, John, Murray, Julie O'Brien Republic of Korea: Ji-In Bang, Henry, Bom, Sang-Geon, Cho, Chae Moon Hong, Su Jin Jang, Yong Hyu Jeong, Won Jun Kang, Ji-Young, Kim, Jaetae, Lee, Chang Kyeong Namgung, Young, So, Kyoung Sook Won Republic of North Macedonia: Venjamin Majstorov, Marija Vavlukis Republic of Slovenia: Barbara Gužic Salobir, Monika Štalc Romania: Theodora Benedek, Imre, Benedek, Raluca, Mititelu, Claudiu Adrian Stan Russian Federation: Alexey Ansheles, Olga, Dariy, Olga, Drozdova, Nina, Gagarina, Vsevolod Milyevich Gulyaev, Irina, Itskovich, Anatoly, Karalkin, Alexander, Kokov, Ekaterina, Migunova, Viktor, Pospelov, Daria, Ryzhkova, Guzaliya, Saifullina, Svetlana, Sazonova, Vladimir, Sergienko, Irina, Shurupova, Tatjana, Trifonova, Wladimir Yurievich Ussov, Margarita, Vakhromeeva, Nailya, Valiullina, Konstantin, Zavadovsky, Kirill Zhuravlev Saudi Arabia: Mirvat Alasnag, Subhani Okarvi Serbia: Dragana Sobic Saranovic Singapore: Felix Keng, Jia Hao Jason See, Ramkumar, Sekar, Min Sen Yew Slovak Republic: Andrej Vondrak South Africa: Shereen Bejai, George, Bennie, Ria, Bester, Gerrit, Engelbrecht, Osayande, Evbuomwan, Harlem, Gongxeka, Magritha Jv Vuuren, Mitchell, Kaplan, Purbhoo, Khushica, Hoosen, Lakhi, Lizette, Louw, Nico, Malan, Katarina, Milos, Moshe, Modiselle, Stuart, More, Mathava, Naidoo, Leonie, Scholtz, Mboyo Vangu Spain: Santiago Aguadé-Bruix, Isabel, Blanco, Antonio, Cabrera, Alicia, Camarero, Irene, Casáns-Tormo, Hug, Cuellar-Calabria, Albert, Flotats, Maria Eugenia Fuentes Cañamero, María Elia García, Amelia, Jimenez-Heffernan, Rubén, Leta, Javier Lopez Diaz, Luis, Lumbreras, Juan Javier Marquez-Cabeza, Francisco, Martin, Anxo Martinez de Alegria, Francisco, Medina, Maria Pedrera Canal, Virginia, Peiro, Virginia, Pubul-Nuñez, Juan Ignacio Rayo Madrid, Cristina Rodríguez Rey, Ricardo Ruano Perez, Joaquín, Ruiz, Gertrudis Sabatel Hernández, Ana, Sevilla, Nahla Zeidán Sri Lanka: Damayanthi Nanayakkara, Chandraguptha Udugama Sweden: Magnus Simonsson Switzerland: Hatem Alkadhi, Ronny Ralf Buechel, Peter, Burger, Luca, Ceriani, Bart De Boeck, Christoph, Gräni, Alix Juillet de Saint Lager Lucas, Kamani, Christel H., Nadine, Kawel-Boehm, Robert, Manka, Prior, John O., Axel, Rominger, Jean-Paul Vallée Thailand: Benjapa Khiewvan, Teerapon, Premprabha, Tanyaluck Thientunyakit Tunisia: Ali Sellem Turkey: Kemal Metin Kir, Haluk Sayman Uganda: Mugisha Julius Sebikali, Zerida Muyinda Ukraine: Yaroslav Kmetyuk, Pavlo, Korol, Olena, Mykhalchenko, Volodymyr, Pliatsek, Maryna Satyr United Arab Emirates: Batool Albalooshi, Mohamed Ismail Ahmed Hassan United Kingdom: Jill Anderson, Punit, Bedi, Thomas, Biggans, Anda, Bularga, Russell, Bull, Rajesh, Burgul, John-Paul, Carpenter, Duncan, Coles, David, Cusack, Aparna, Deshpande, John, Dougan, Timothy, Fairbairn, Alexia, Farrugia, Deepa, Gopalan, Alistair, Gummow, Prasad Guntur Ramkumar, Mark, Hamilton, Mark, Harbinson, Thomas, Hartley, Benjamin, Hudson, Nikhil, Joshi, Michael, Kay, Andrew, Kelion, Azhar, Khokhar, Jamie, Kitt, Ken, Lee, Chen, Low, Sze Mun Mak, Ntouskou, Marousa, Jon, Martin, Elisa, Mcalindon, Leon, Menezes, Gareth, Morgan-Hughes, Alastair, Moss, Anthony, Murray, Edward, Nicol, Dilip, Patel, Charles, Peebles, Francesca, Pugliese, Jonathan Carl Luis Rodrigues, Christopher, Rofe, Nikant, Sabharwal, Rebecca, Schofield, Thomas, Semple, Naveen, Sharma, Peter, Strouhal, Deepak, Subedi, William, Topping, Katharine, Tweed, Jonathan Weir-Mccall United States of America: Suhny Abbara, Taimur, Abbasi, Brian, Abbott, Shady, Abohashem, Sandra, Abramson, Tarek, Al-Abboud, Mouaz, Al-Mallah, Omar, Almousalli, Karthikeyan, Ananthasubramaniam, Mohan Ashok Kumar, Jeffrey, Askew, Lea, Attanasio, Mallory, Balmer-Swain, Bayer, Richard R., Adam, Bernheim, Sabha, Bhatti, Erik, Bieging, Ron, Blankstein, Stephen, Bloom, Sean, Blue, David, Bluemke, Andressa, Borges, Kelley, Branch, Paco, Bravo, Jessica, Brothers, Matthew, Budoff, Renée, Bullock-Palmer, Angela, Burandt, Burke, Floyd W., Kelvin, Bush, Candace, Candela, Elizabeth, Capasso, Joao, Cavalcante, Donald, Chang, Saurav, Chatterjee, Yiannis, Chatzizisis, Michael, Cheezum, Tiffany, Chen, Jennifer, Chen, Marcus, Chen, Andrew, Choi, James, Clarcq, Ayreen, Cordero, Matthew, Crim, Sorin, Danciu, Bruce, Decter, Nimish, Dhruva, Neil, Doherty, Rami, Doukky, Anjori, Dunbar, William, Duvall, Rachael, Edwards, Kerry, Esquitin, Husam, Farah, Emilio, Fentanes, Maros, Ferencik, Daniel, Fisher, Daniel, Fitzpatrick, Cameron, Foster, Tony, Fuisz, Michael, Gannon, Lori, Gastner, Myron, Gerson, Brian, Ghoshhajra, Alan, Goldberg, Brian, Goldner, Jorge, Gonzalez, Rosco, Gore, Sandra, Gracia-López, Fadi, Hage, Agha, Haider, Sofia, Haider, Yasmin, Hamirani, Karen, Hassen, Mallory, Hatfield, Carolyn, Hawkins, Katie, Hawthorne, Nicholas, Heath, Robert, Hendel, Phillip, Hernandez, Gregory, Hill, Stephen, Horgan, Jeff, Huffman, Lynne, Hurwitz, Ami, Iskandrian, Rajesh, Janardhanan, Christine, Jellis, Scott, Jerome, Dinesh, Kalra, Summanther, Kaviratne, Fernando, Kay, Faith, Kelly, Omar, Khalique, Mona, Kinkhabwala, George Kinzfogl Iii, Jacqueline, Kircher, Rachael, Kirkbride, Michael, Kontos, Anupama, Kottam, Joseph, Krepp, Jay, Layer, Steven, H Lee, Jeffrey, Leppo, John, Lesser, Steve, Leung, Howard, Lewin, Diana, Litmanovich, Yiyan, Liu, Juan, Lopez-Mattei, Kathleen, Magurany, Jeremy, Markowitz, Amanda, Marn, Stephen, E Matis, Michael, Mckenna, Tony, Mcrae, Fernando, Mendoza, Michael, Merhige, David, Min, Chanan, Moffitt, Karen, Moncher, Warren, Moore, Shamil, Morayati, Michael, Morris, Mahmud, Mossa-Basha, Zorana, Mrsic, Venkatesh, Murthy, Prashant, Nagpal, Kyle, Napier, Jagat, Narula, Katarina, Nelson, Prabhjot, Nijjar, Medhat, Osman, Purvi, Parwani, Edward, Passen, Amit, Patel, Pravin, Patil, Ryan, Paul, Lawrence, Phillips, Venkateshwar, Polsani, Rajaram, Poludasu, Brian, Pomerantz, Thomas, Porter, Ryan, Prentice, Amit, Pursnani, Mark, Rabbat, Suresh, Ramamurti, Florence, Rich, Hiram Rivera Luna, Austin, Robinson, Kim, Robles, Cesar, Rodríguez, Mark, Rorie, John, Rumberger, Raymond, Russell, Philip, Sabra, Diego, Sadler, Mary, Schemmer, Joseph Schoepf, U., Samir, Shah, Nishant, Shah, Sujata, Shanbhag, Gaurav, Sharma, Steven, Shayani, Jamshid, Shirani, Pushpa, Shivaram, Steven, Sigman, Mitch, Simon, Ahmad, Slim, David, Smith, Alexandra, Smith, Prem, Soman, Aditya, Sood, Monvadi Barbara Srichai-Parsia, James, Streeter, Albert, T, Ahmed, Tawakol, Dustin, Thomas, Randall, Thompson, Tara, Torbet, Desiree, Trinidad, Shawn, Ullery, Samuel, Unzek, Seth, Uretsky, Srikanth, Vallurupalli, Vikas, Verma, Alfonso, Waller, Ellen, Wang, Parker, Ward, Gaby, Weissman, George, Wesbey, Kelly, White, David, Winchester, David, Wolinsky, Sandra, Yost, Michael Zgaljardic Uruguay: Omar Alonso, Mario, Beretta, Rodolfo, Ferrando, Miguel, Kapitan, Fernando Mut Uzbekistan: Omoa Djuraev, Gulnora Rozikhodjaeva Vietnam: Ha Le Ngoc, Son Hong Mai, and Xuan Canh Nguyen
- Subjects
medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Cardiology ,Settore MED/11 - Malattie dell'Apparato Cardiovascolare ,COVID-19 ,Cardiac imaging ,Cardiovascular disease ,Article ,cardiac imaging ,Healthcare delivery ,cardiovascular disease ,Intensive care ,Surveys and Questionnaires ,Health care ,Pandemic ,medicine ,Humans ,Pandemics ,Protocol (science) ,business.industry ,SARS-CoV-2 ,Non invasive ,Italy ,humans ,pandemics ,surveys and questionnaires ,cardiology ,Emergency medicine ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background: In early 2020, COVID-19 massively hit Italy, earlier and harder than any other European country. This caused a series of strict containment measures, aimed at blocking the spread of the pandemic. Healthcare delivery was also affected when resources were diverted towards care of COVID-19 patients, including intensive care wards. Aim of the study: The aim is assessing the impact of COVID-19 on cardiac imaging in Italy, compare to the Rest of Europe (RoE) and the World (RoW). Methods: A global survey was conducted in May–June 2020 worldwide, through a questionnaire distributed online. The survey covered three periods: March and April 2020, and March 2019. Data from 52 Italian centres, a subset of the 909 participating centres from 108 countries, were analyzed. Results: In Italy, volumes decreased by 67% in March 2020, compared to March 2019, as opposed to a significantly lower decrease (p < 0.001) in RoE and RoW (41% and 40%, respectively). A further decrease from March 2020 to April 2020 summed up to 76% for the North, 77% for the Centre and 86% for the South. When compared to the RoE and RoW, this further decrease from March 2020 to April 2020 in Italy was significantly less (p = 0.005), most likely reflecting the earlier effects of the containment measures in Italy, taken earlier than anywhere else in the West. Conclusions: The COVID-19 pandemic massively hit Italy and caused a disruption of healthcare services, including cardiac imaging studies. This raises concern about the medium- and long-term consequences for the high number of patients who were denied timely diagnoses and the subsequent lifesaving therapies and procedures.
- Published
- 2021
- Full Text
- View/download PDF
33. Clinical performance of calcitonin and procalcitonin Elecsys
- Author
-
Luca, Giovanella, Martina, Fontana, Franco, Keller, Frederik A, Verburg, and Luca, Ceriani
- Subjects
Calcitonin ,Immunoassay ,Thyroid Cancer, Papillary ,Biomarkers, Tumor ,Humans ,Thyroid Neoplasms ,Procalcitonin ,Carcinoma, Neuroendocrine - Abstract
Medullary thyroid carcinoma (MTC) is caused by a malignant transformation in the parafollicular C-cells of the thyroid, where calcitonin (CT) is released. Nowadays, CT is the main tumor marker used in the diagnosis and follow-up of MTC patients. Nonetheless, procalcitonin (PCT) has recently been proposed as a useful complementary/alternative biomarker in MTC. Our aims were to investigate the diagnostic performance of CT and PCT and their combination in the differential diagnosis between active and inactive MTC and between MTC and non-MTC thyroid diseases, respectively.Serum samples were collected from 16 patients with active (i.e. primary tumour before surgery or post-surgical recurrent disease) and 23 with inactive (i.e. complete remission) MTC, 125 patients with non-MTC benign thyroid disease and 62 patients with non-MTC thyroid cancers, respectively. ElecsysBoth CT and PCT median values in active MTC (94 pmol/L and 1.17 ng/mL, respectively) were significantly higher compared with inactive MTC (0.28 and 0.06) and either benign (0.37 and 0.06) or malignant (0.28 and 0.06) non-MTC. Undetectable PCT was found in five non-MTC patients with false positive CT results.Elecsys
- Published
- 2020
34. Author response for 'Prognostic Models Integrating Quantitative Parameters from Baseline and Interim Positron Emission Computed Tomography in Patients with Diffuse Large B‐Cell Lymphoma: Post‐Hoc Analysis from the SAKK38/07 Clinical Trial'
- Author
-
null Emanuele Zucca, null Luciano Cascione, null Teresa Ruberto, null Davide Facchinelli, null Sämi Schär, null Stefanie Hayoz, null Stefan Dirnhofer, null Luca Giovanella, null Mario Bargetzi, null Christoph Mamot, and null Luca Ceriani
- Published
- 2020
- Full Text
- View/download PDF
35. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial
- Author
-
Christoph Mamot, Emanuele Zucca, Luca Ceriani, Stefan Dirnhofer, Davide Facchinelli, Teresa Ruberto, Luciano Cascione, Luca Giovanella, Mario Bargetzi, Sämi Schär, and Stefanie Hayoz
- Subjects
Male ,Cancer Research ,Vincristine ,Standardized uptake value ,Kaplan-Meier Estimate ,03 medical and health sciences ,0302 clinical medicine ,International Prognostic Index ,Positron Emission Tomography Computed Tomography ,Post-hoc analysis ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Positron emission ,Cyclophosphamide ,business.industry ,Hematology ,General Medicine ,medicine.disease ,Prognosis ,Clinical trial ,Oncology ,ROC Curve ,Doxorubicin ,030220 oncology & carcinogenesis ,Prednisone ,Rituximab ,Female ,Lymphoma, Large B-Cell, Diffuse ,business ,Nuclear medicine ,Diffuse large B-cell lymphoma ,Biomarkers ,030215 immunology ,medicine.drug - Abstract
Positron emission computed tomography (PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) enrolled in a prospective clinical trial were reviewed to test the impact of quantitative parameters from interim PET/CT scans on overall (OS) and progression-free (PFS) survival. We centrally reviewed baseline and interim PET/CT scans of 138 patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone given every 14 days (R-CHOP14) in the SAKK38/07 trial (ClinicalTrial.gov identifier: NCT00544219). Cutoff values for maximum standardized uptake value (SUVmax ), metabolic tumor volume (MTV), total lesion glycolysis (TLG) and metabolic heterogeneity (MH) were defined by receiver operating characteristic analysis. Responses were scored using the Deauville scale (DS). Patients with DS 5 at interim PET/CT (defined by uptake >2 times higher than in normal liver) had worse PFS (P = 0.014) and OS (P < 0.0001). A SUVmax reduction (Δ) greater than 66% was associated with longer PFS (P = 0.0027) and OS (P < 0.0001). Elevated SUVmax , MTV, TLG, and MH at interim PET/CT also identified patients with poorer outcome. At multivariable analysis, ΔSUVmax and baseline MTV appeared independent outcome predictors. A prognostic model integrating ΔSUVmax and baseline MTV discriminated three risk groups with significantly (log-rank test for trend, P < 0.0001) different PFS and OS. Moreover, the integration of MH and clinical prognostic indices could further refine the prediction of OS. PET metrics-derived prognostic models perform better than the international indices alone. Integration of baseline and interim PET metrics identified poor-risk DLBCL patients who might benefit from alternative treatments.
- Published
- 2020
36. Radiomics Analysis of [
- Author
-
Luca, Ceriani, Lisa, Milan, Camilla, Virili, Luciano, Cascione, Gaetano, Paone, Pierpaolo, Trimboli, and Luca, Giovanella
- Subjects
Male ,Incidental Findings ,Databases, Factual ,Reproducibility of Results ,Middle Aged ,Prognosis ,Risk Assessment ,Fluorodeoxyglucose F18 ,Predictive Value of Tests ,Risk Factors ,Positron Emission Tomography Computed Tomography ,Humans ,Female ,Whole Body Imaging ,Thyroid Neoplasms ,Radiopharmaceuticals ,Aged ,Retrospective Studies - Published
- 2020
37. Additional value of integrated 18F-choline PET/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile
- Author
-
P. Del Monte, Gianluca Bottoni, Anna Crescenzi, Arnoldo Piccardo, L. Giovanella, Anselmo Arlandini, Lorenzo Bacigalupo, Luca Ceriani, Luca Foppiani, Manlio Cabria, Ugo Catrambone, Matteo Puntoni, M. Lanata, Giulia Ferrarazzo, Gaetano Paone, Pierpaolo Trimboli, Francesco Paparo, Mariangela Rutigliani, and Giorgio Treglia
- Subjects
Hyperparathyroidism ,medicine.medical_specialty ,business.industry ,media_common.quotation_subject ,General Medicine ,medicine.disease ,030218 nuclear medicine & medical imaging ,Correlation ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,medicine ,Immunohistochemistry ,Contrast (vision) ,Radiology, Nuclear Medicine and imaging ,Molecular Profile ,Histopathology ,Parathyroid gland ,business ,Nuclear medicine ,Primary hyperparathyroidism ,media_common - Abstract
The localization of hyperfunctioning parathyroid gland(s) (HPTG) in patients with primary hyperparathyroidism (PHPT) with negative or inconclusive first-line imaging is a significant challenge. This study aimed to evaluate the role of integrated 18F-choline PET/4D contrast-enhanced computed tomography (4DCeCT) in these patients, compare its detection rate and sensitivity with those of 18F-choline PET/CT and (4DCeCT), and analyse the association between choline metabolism and morphological, biochemical and molecular parameters of HPTG. We prospectively enrolled 44 PHPT patients with negative or inconclusive first-line imaging. 18F-Choline PET/CT and 4DCeCT were performed at the same time, and integrated 18F-choline PET/4DCeCT images were obtained after coregistration. Experienced physicians examined the images. The SUVratio and degree of contrast enhancement were recorded for each positive finding. Histopathology, laboratory and multidisciplinary follow-up were used as the standard of reference. Both the detection rates and sensitivities of the three imaging modalities were calculated retrospectively. Immunohistochemistry was performed to evaluate the molecular profile of HPTGs. 18F-Choline PET/4DCeCT was positive in 32 of 44 patients with PHPT (detection rate 72.7%), and 31 of 31 surgically treated patients (sensitivity 100%). These results were significantly (p
- Published
- 2018
- Full Text
- View/download PDF
38. Euthyroid Graves’ disease with spurious hyperthyroidism: a diagnostic challenge
- Author
-
Mauro Imperiali, Pierpaolo Trimboli, Luca Ceriani, Dusanka Kasapic, and Luca Giovanella
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Multiple sclerosis ,Graves' disease ,Biochemistry (medical) ,Clinical Biochemistry ,Thyroid ,MEDLINE ,General Medicine ,medicine.disease ,Thyroid function tests ,Gastroenterology ,medicine.anatomical_structure ,Internal medicine ,Medicine ,Euthyroid ,business - Published
- 2019
- Full Text
- View/download PDF
39. Multiple abdominal artery dissections: how to distinguish two rare diseases
- Author
-
Silvio Pianca, Sara De Marchi, Luca Ceriani, and Pietro E. Cippà
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Dissection ,Acute abdominal pain ,Interventional radiology ,Computed tomography ,Renal medicine ,General Medicine ,Middle Aged ,medicine.disease ,Rare Diseases ,Renal Artery ,Mesenteric Artery, Superior ,medicine.artery ,medicine ,Humans ,Female ,Stents ,Radiology ,Superior mesenteric artery ,Abdominal artery ,Vasculitis ,business - Abstract
A 59-year-old woman was referred to the emergency room with acute abdominal pain. A CT scan revealed multiple dissections and microaneurysms of the superior mesenteric, the hepatic and the renal arteries. Stenting of the superior mesenteric artery was required. A non-invasive diagnostic procedure was instrumental to establish the diagnosis and guide appropriate treatment, which resulted in a rapid and sustained recovery.
- Published
- 2021
- Full Text
- View/download PDF
40. American Thyroid Association ultrasound system for the initial assessment of thyroid nodules: Use in stratifying the risk of malignancy of indeterminate lesions
- Author
-
PD Luca Giovanella Md, Maurilio Deandrea, Francesca Garino, Alberto Mormile, Pierpaolo Trimboli, Luca Ceriani, and Paolo Piero Limone
- Subjects
Male ,Thyroid nodules ,medicine.medical_specialty ,Multivariate analysis ,Biopsy, Fine-Needle ,030209 endocrinology & metabolism ,Malignancy ,Sensitivity and Specificity ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,medicine ,Humans ,Neoplasm Invasiveness ,Thyroid Neoplasms ,Thyroid Nodule ,Societies, Medical ,Ultrasonography, Interventional ,Aged ,Neoplasm Staging ,Retrospective Studies ,business.industry ,Ultrasound ,Thyroid ,Cancer ,Odds ratio ,Middle Aged ,medicine.disease ,Immunohistochemistry ,United States ,Cell Transformation, Neoplastic ,medicine.anatomical_structure ,ROC Curve ,Otorhinolaryngology ,030220 oncology & carcinogenesis ,Female ,Radiology ,Indeterminate ,business - Abstract
The ultrasound risk stratification system of the American Thyroid Association (ATA) is frequently adopted in clinical practice. Here, we evaluated its performance in a series of nodules with indeterminate fine-needle aspiration cytology (FNAC) report.Indeterminate thyroid nodules diagnosed at 2 medical centers were retrospectively screened, ultrasound images were reevaluated, and lesions were classified according to the ATA. Single ultrasound parameters were also analyzed.One hundred seventy-three indeterminate lesions were included with 24.8% of malignancy. The high suspicion class showed a cancer rate (75%) significantly (P.001) higher than that recorded in the other categories (16.8%). Between ultrasound parameters, halo and microcalcifications were the most sensitive and specific ones. The most accurate receiver operating characteristic (ROC)-derived cutoff of nodule's diameter was4.1 cm. At multivariate analysis, only the ATA class of high suspicion and size4.1 cm were significantly associated with cancer (odds ratios [ORs] 19.4 and 5.4, respectively).The ATA ultrasound system is reliable in the risk stratification of indeterminate thyroid lesions.
- Published
- 2017
- Full Text
- View/download PDF
41. Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System
- Author
-
Maurizio Simmaco, Pierpaolo Trimboli, Sebastiano Vottari, Luca Giovanella, Agnese Barnabei, Marialuisa Appetecchia, Giulia Ferrarazzo, Alfonsina Chiefari, Stefano Valabrega, Arnoldo Piccardo, Alberto Signore, Arianna Di Paolo, Luca Ceriani, Valeria Stati, and Giuliano Santolamazza
- Subjects
Oncology ,Adult ,Male ,endocrine system ,medicine.medical_specialty ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,Thyroid Gland ,030209 endocrinology & metabolism ,carcinoma ,elderly ,age ,recurrence ,thyroid ,TNM ,Thyroid carcinoma ,Iodine Radioisotopes ,03 medical and health sciences ,NODULES ,0302 clinical medicine ,Endocrinology ,Patient age ,Recurrence ,Risk Factors ,Internal medicine ,Adenocarcinoma, Follicular ,Carcinoma ,Medicine ,Humans ,Thyroid Neoplasms ,Neoplasm Staging ,business.industry ,7TH ,Thyroid ,Age Factors ,8TH EDITIONS ,STAGING SYSTEM ,Middle Aged ,medicine.disease ,CANCER ,MANAGEMENT GUIDELINES ,medicine.anatomical_structure ,Thyroid Cancer, Papillary ,030220 oncology & carcinogenesis ,CUTOFF ,Thyroidectomy ,Female ,Neoplasm Recurrence, Local ,business - Abstract
Background: The 2015 American Thyroid Association (ATA) guidelines proposed a three-category system for estimating the risk of recurrence of differentiated thyroid carcinoma (DTC). This system includes several perioperative features, but not age at diagnosis. However, age has traditionally been recognized as a critical factor in the survival of DTC patients, and the eighth edition of TNM stated that patients older than 55 years were at higher risk of death. In this study, we raised the question of whether age at DTC diagnosis impacts on its risk of recurrence. Specifically, the present study aimed to (i) evaluate the association between age at diagnosis and structural recurrence and (ii) investigate whether age at diagnosis could improve the performance of the ATA system.Methods: During the study period, four institutions selected DTC patients treated with both thyroidectomy and radioiodine and who had follow-up for at least one year. Patients with proven structural evidence of disease during follow-up were identified, and disease-free survival (DFS) was calculated accordingly.Results: The study involved 1603 DTC patients with a median age of 49 years and DFS of 44 months. Disease recurred in 8%. The shortest DFS was found in the oldest patients. The Kaplan-Meier curves were calculated for each decade of age, and there was a significant association with DFS (p = 0.0014). Patients older than 55 years had significantly higher risk (hazard ratio [HR] 1.78, 95% confidence interval [CI 1.23-2.56]). The Kaplan-Meier curves of DFS in high-, intermediate- and low-risk groups showed a significant association only in the high-risk group (p = 0.0058). Patients older than 55 years had significantly higher risk of relapse over time only in the high-risk group (HR 2.15 [CI 2.01-4.53]). Cox's proportional analysis showed that the age cutoff of 55 years and the ATA system were significant predictors of relapse. Adding age at diagnosis above 55 years to the ATA system identified a subgroup of patients at highest risk for relapse.Conclusions: The age threshold adopted in the eighth edition of TNM staging system for DTC patients' prognosis also identifies cases at higher risk of relapse. Applying age at diagnosis, with a cutoff of 55 years, to the ATA risk stratification system identifies cases at highest risk of relapse.
- Published
- 2020
42. Meta-Analyses on Technical Aspects of PET
- Author
-
Luca Ceriani
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,Computer science ,Positron emission tomography ,media_common.quotation_subject ,medicine ,Medical physics ,Quality (business) ,media_common - Abstract
In literature, there are few meta-analyses that have addressed technical and methodological issues concerning positron emission tomography (PET) imaging despite their important role in determining the quality of the diagnostic results [1–19].
- Published
- 2020
- Full Text
- View/download PDF
43. Role of
- Author
-
Arnoldo, Piccardo, Pierpaolo, Trimboli, Matteo, Puntoni, Luca, Foppiani, Giorgio, Treglia, Mehrdad, Naseri, Gian Luca, Bottoni, Michela, Massollo, Simona, Sola, Giulia, Ferrarazzo, Martina, Bruzzone, Ugo, Catrambone, Anselmo, Arlandini, Gaetano, Paone, Luca, Ceriani, Manlio, Cabria, and Luca, Giovanella
- Subjects
Male ,Time Factors ,Reproducibility of Results ,Cell Differentiation ,Middle Aged ,Risk Assessment ,Choline ,Iodine Radioisotopes ,Treatment Outcome ,Italy ,Fluorodeoxyglucose F18 ,Predictive Value of Tests ,Risk Factors ,Positron Emission Tomography Computed Tomography ,Thyroidectomy ,Humans ,Female ,Prospective Studies ,Thyroid Neoplasms ,Neoplasm Recurrence, Local ,Radiopharmaceuticals ,Switzerland ,Aged - Abstract
This study aimed to evaluate the role ofThe study prospectively enrolled high-risk DTC patients treated with thyroidectomy and radioactive iodine therapy and presenting high/increasing thyroglobulin levels under thyrotropin suppression, negative/inconclusive neck ultrasound, and negativeTwenty-five high-risk DTC patients were included; DTC relapse/persistence was confirmed in 23 patients. On PBA
- Published
- 2019
44. Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma
- Author
-
Attilio Guarini, Umberto Ricardi, Annalisa Chiappella, David Cunningham, Peter Johnson, Pier Luigi Zinzani, Maurizio Martelli, Luca Giovanella, Luca Ceriani, Caterina Stelitano, Monica Balzarotti, Maria K. Gospodarowicz, Andrés J.M. Ferreri, Emanuele Zucca, Maria Elena Cabrera, Ceriani, Luca, Martelli, Maurizio, Gospodarowicz, Maria K., Ricardi, Umberto, Ferreri, Andrés J.M., Chiappella, Annalisa, Stelitano, Caterina, Balzarotti, Monica, Cabrera, Maria E., Cunningham, David, Guarini, Attilio, Zinzani, Pier Luigi, Giovanella, Luca, Johnson, Peter W.M., and Zucca, Emanuele
- Subjects
Male ,Radiation ,Oncology ,Radiology, Nuclear Medicine and Imaging ,Cancer Research ,Lymphoma ,medicine.medical_treatment ,Leucovorin ,0302 clinical medicine ,Recurrence ,Prednisone ,Positron Emission Tomography Computed Tomography ,Nuclear Medicine and Imaging ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Prospective Studies ,Prospective cohort study ,Etoposide ,medicine.diagnostic_test ,Conformal ,Statistics ,Radiotherapy Dosage ,Liver ,Vincristine ,Positron emission tomography ,Residual ,030220 oncology & carcinogenesis ,Disease Progression ,Female ,Immunotherapy ,Rituximab ,Radiology ,medicine.drug ,Adult ,Bleomycin ,Cyclophosphamide ,Disease-Free Survival ,Doxorubicin ,Humans ,Lymphoma, B-Cell ,Mediastinal Neoplasms ,Methotrexate ,Neoplasm, Residual ,Radiotherapy, Conformal ,Statistics, Nonparametric ,Young Adult ,Fluorodeoxyglucose F18 ,Radiopharmaceuticals ,03 medical and health sciences ,Nonparametric ,Radiology, Nuclear Medicine and imaging ,Radiotherapy ,business.industry ,B-Cell ,medicine.disease ,Mediastinal Neoplasm ,Radiation therapy ,Neoplasm ,Primary mediastinal B-cell lymphoma ,business ,Nuclear medicine ,030215 immunology - Abstract
Purpose To assess the predictive value of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) for disease recurrence after immunochemotherapy (R-CHT) and mediastinal irradiation (RT), using the recently published criteria of the Lugano classification to predict outcomes for patients with primary mediastinal large B-cell lymphoma. Methods and Materials Among 125 patients prospectively enrolled in the IELSG-26 study, 88 were eligible for central review of PET/CT scans after completion of RT. Responses were evaluated using the 5-point Deauville scale at the end of induction R-CHT and after consolidation RT. According to the Lugano classification, a complete metabolic response (CMR) was defined by a Deauville score (DS) ≤3. Results The CMR (DS1, -2, or -3) rate increased from 74% (65 patients) after R-CHT to 89% (78 patients) after consolidation RT. Among the 10 patients (11%) with persistently positive scans, the residual uptake after RT was slightly higher than the liver uptake in 6 patients (DS4; 7%) and markedly higher in 4 patients (DS5; 4%): these patients had a significantly poorer 5-year progression-free survival and overall survival. At a median follow-up of 60 months (range, 35-107 months), no patients with a CMR after RT have relapsed. Among the 10 patients who did not reach a CMR, 3 of the 4 patients (positive predictive value, 75%) with DS5 after RT had subsequent disease progression (within the RT volume in all cases) and died. All patients with DS4 had good outcomes without recurrence. Conclusions All the patients obtaining a CMR defined as DS ≤3 remained progression-free at 5 years, confirming the excellent negative predictive value of the Lugano classification criteria in primary mediastinal large B-cell lymphoma patients. The few patients with DS4 also had an excellent outcome, suggesting that they do not necessarily require additional therapy, because the residual 18 F-fluorodeoxyglucose uptake may not reflect persistent lymphoma.
- Published
- 2017
- Full Text
- View/download PDF
45. Accuracy of international ultrasound risk stratification systems in thyroid lesions cytologically classified as indeterminate
- Author
-
Luca Giovanella, Franco Fulciniti, Pierpaolo Trimboli, Valentina Zilioli, and Luca Ceriani
- Subjects
Thyroid nodules ,medicine.medical_specialty ,Histology ,business.industry ,Thyroid ,Ultrasound ,030209 endocrinology & metabolism ,Nodule (medicine) ,General Medicine ,Thyroid ultrasound ,medicine.disease ,Pathology and Forensic Medicine ,Clinical Practice ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Risk stratification ,medicine ,Radiology ,medicine.symptom ,Indeterminate ,business - Abstract
Background Eminent international societies have published their thyroid ultrasound risk stratification system (US-RSS) to give a friendly tool for thyroidologists. In particular, American Thyroid Association (ATA), American Association Clinical Endocrinologists/American College of Endocrinologists and Associazione Medici Endocrinologi (AACE/ACE/AME), British Thyroid Association (BTA), and Thyroid Imaging Reporting and Data System (TIRADS) are often adopted for clinical practice. The reliability of these US-RSS has not been evaluated in discriminating cancers from benignancy in nodules with indeterminate FNA. Methods Indeterminate thyroid lesions were searched in our database and only those with histology were finally included. The matching of US and histologic data of nodule's location and size were verified. All US images and clips were re-evaluated and nodules classified according to the above US-RSS. Results A series of 101 indeterminate lesions, diagnosed by FNA were included (mean size 2.4 cm) and a 21% of cancers was found at histology. When all lesions were classified by US-RSS, poor accuracy (up to 54%) and specificity (up to 19%) were recorded. Highest sensitivity (91%) and NPV (94%) was obtained by BTA. Of relevance, the rate of nodules with indeterminate US risk recorded by BTA was significantly lower than the other (P
- Published
- 2016
- Full Text
- View/download PDF
46. Functional Imaging Using 18-Fluorodeoxyglucose PET in the Management of Primary Mediastinal Large B-Cell Lymphoma: The Contributions of the International Extranodal Lymphoma Study Group
- Author
-
Emanuele Zucca, Franco Cavalli, and Luca Ceriani
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Multimodal Imaging ,Disease-Free Survival ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Fluorodeoxyglucose F18 ,law ,medicine ,Humans ,Stage (cooking) ,medicine.diagnostic_test ,business.industry ,Mediastinum ,General Medicine ,Prognosis ,medicine.disease ,Tumor Burden ,Lymphoma ,Functional imaging ,Radiation therapy ,Treatment Outcome ,medicine.anatomical_structure ,Positron emission tomography ,Positron-Emission Tomography ,030220 oncology & carcinogenesis ,Biomarker (medicine) ,Lymphoma, Large B-Cell, Diffuse ,Radiology ,Neoplasm Recurrence, Local ,Tomography, X-Ray Computed ,Nuclear medicine ,business ,030215 immunology - Abstract
Primary mediastinal large B-cell lymphoma (PMLBCL) is recognized as a distinct disease entity. Treatment outcomes appear better than in other diffuse large B-cell lymphoma (DLBCL) types, partly because of their earlier stage at presentation and the younger age of most patients. If initial treatment fails, however, the results of salvage chemotherapy and myeloablative treatment are poor. The need to avoid relapses after initial therapy has led to controversy over the extent of front-line therapy, particularly whether consolidation radiotherapy to the mediastinum is always required and whether the 18-fluorodeoxyglucose (18F-FDG) uptake detected by PET-CT scan can be used to determine its requirements. Functional imaging using PET-CT generally allows distinguishing of residual mediastinal masses containing active lymphoma from those with only sclerotic material remaining. The International Extranodal Lymphoma Study Group (IELSG) conducted the prospective IELSG-26 study, which showed that a five-point visual scale can be used to define metabolic response after immunochemotherapy and that a cut point based on liver uptake discriminates effectively between high or low risk of failure, with 5-year progression-free survival (PFS) of 99% versus 68% and 5-year overall survival (OS) of 100% versus 83%. This study also showed that a baseline quantitative PET parameter, namely the total lesion glycolysis describing the metabolic tumor burden, can be a powerful predictor of PMLBCL outcomes and warrants further validation as a biomarker. The ongoing IELSG-37 randomized study addresses the need for consolidation mediastinal radiotherapy in patients in whom a complete metabolic response (CMR) can be seen on PET scans after standard immunochemotherapy.
- Published
- 2016
- Full Text
- View/download PDF
47. Present role and future perspective of PET-CT in marginal zone lymphoma
- Author
-
Michel Meignan and Luca Ceriani
- Subjects
PET-CT ,medicine.medical_specialty ,Future perspective ,business.industry ,Marginal zone lymphoma ,Medicine ,General Medicine ,Radiology ,business - Published
- 2020
- Full Text
- View/download PDF
48. Measuring thyroglobulin in patients with thyroglobulin autoantibodies: evaluation of the clinical impact of BRAHMS Kryptor® Tg-minirecovery test in a large series of patients with differentiated thyroid carcinoma
- Author
-
Franco Keller, Luca Giovanella, Pierpaolo Trimboli, Frederik A. Verburg, Mauro Imperiali, and Luca Ceriani
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Clinical Biochemistry ,030209 endocrinology & metabolism ,Thyroid Function Tests ,Gastroenterology ,Thyroglobulin ,Thyroid carcinoma ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,medicine ,Recurrent disease ,Humans ,In patient ,Thyroid Neoplasms ,Aged ,Autoantibodies ,Immunoassay ,business.industry ,Biochemistry (medical) ,Autoantibody ,Curve analysis ,Large series ,General Medicine ,Middle Aged ,030220 oncology & carcinogenesis ,Referral center ,Female ,business ,Blood Chemical Analysis - Abstract
Background The present study was undertaken to evaluate the clinical impact of a thyroglobulin (Tg) minirecovery test (Tg-mRec) in a large series of differentiated thyroid carcinoma (DTC) patients treated and monitored homogeneously in a tertiary referral center. Methods Included were 1120 serum samples from 798 DTC patients. Tg, Tg autoantibodies (TgAb) and Tg-mrec measurements were performed on the automated Kryptor® platform and results compared to the corresponding clinical status. Results Among included samples 228 (20%) were TgAb-positive (TgAb+) and 892 (80%) TgAb-negative (TgAb−), respectively. Tg cutoff points were settled at 0.31 μg/L and 0.15 μg/L for TgAb− and TgAb+ patients, respectively, by ROC curve analysis. The diagnostic performance of serum Tg was reduced in TgAb+ compared to TgAb− patients, however, 87% of TgAb+ patients with recurrent disease and, particularly, all patients with distant metastases were correctly detected by adopting an optimized Tg cutoff for TgAb+ patients. A disturbed recovery was found in only 1% of TgAb− patients and in these cases no clinically relevant information was added by the Tg-mRec. Among TgAb+ patients with undetectable Tg and undisturbed Tg-mRec, no one had recurrent disease. However, a falsely undetectable Tg was demonstrated in two patients with recurrent disease who next to increased TgAb also had a disturbed Tg-mRec test. Conclusions There is no additional clinical benefit from performing Tg-mRec in most patients. It can however be considered in TgAb+ patients with undetectable Tg levels as it may help differentiate between patients with true negative and false negative Tg levels in the presence of such antibodies.
- Published
- 2018
49. A 'ring of fire' around the heart: pericarditis detected by FDG-PET/CT
- Author
-
Luca Giovanella, Giorgio Treglia, Luca Ceriani, and Mariana Raditchkova
- Subjects
PET-CT ,medicine.diagnostic_test ,business.industry ,Ring (chemistry) ,medicine.disease ,Pericarditis ,Positron emission tomography ,Risk stratification ,Medicine ,Fdg pet ct ,Therapy monitoring ,In patient ,Cardiology and Cardiovascular Medicine ,business ,Nuclear medicine - Abstract
FDG-PET/CT enables direct visualisation of inflammatory activity and may represent a useful tool for diagnosis, risk stratification and therapy monitoring in patients with pericarditis.
- Published
- 2018
- Full Text
- View/download PDF
50. Fine-needle aspiration in all thyroid incidentalomas at
- Author
-
Pierpaolo, Trimboli, Gaetano, Paone, Giorgio, Treglia, Camilla, Virili, Teresa, Ruberto, Luca, Ceriani, Arnoldo, Piccardo, and Luca, Giovanella
- Subjects
Male ,Fluorodeoxyglucose F18 ,Positron Emission Tomography Computed Tomography ,Biopsy, Fine-Needle ,Thyroid Gland ,Humans ,Female ,Thyroid Neoplasms ,Thyroid Nodule ,Middle Aged - Abstract
Focal thyroid incidentalomas (TIs) are observed in 2% ofWe retrospectively reviewedAccording to the selection criteria, 75 TIs, being 13 (17.3%) malignant and 62 (82.7%) benign, were included. Cancers had significantly higher SUVmax and SUVmax ratio (Mann-Whitney P 0.01) than benign, and the most accurate cut-offs were7.1 and3.65, respectively. At ultrasound, the cancer rate was 0% in EU-TIRADS 2, 2.9% in EU-TIRADS 3, 4.2% in EU-TIRADS 4% and 78.6% in EU-TIRADS 5 (chi-squared P 0.001). Sensitivity, specificity, PPV, NPV and accuracy for malignancy were 92%, 64%, 35%, 98% and 69% for SUVmax; 85%, 68%, 36%, 96% and 71% for SUVmax ratio; and 85%, 95%, 79%, 97% and 93% for EU-TIRADS, respectively. The absence of all these three features reached a specificity of 97.1%.EU-TIRADS, within a clinical careful approach, can discriminate with significant accuracy lesions at high risk of malignancy from those at low risk among TIs at
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.